fluorouracil and Hepatocellular Carcinoma studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

Excerpt	Relevance	Reference
"Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC)."	9.51	Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). ( Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M, 2022)
"A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies."	9.41	A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. ( Changou, CA; Chen, LT; Cheng, YC; Liu, S; Liu, SH; Luh, F; Shiah, HS; Yen, Y, 2021)
"Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit."	9.30	Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. ( Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R, 2019)
"In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior."	9.27	Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. ( Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K, 2018)
"The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)."	9.24	A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017)
"Raltitrexed has shown efficacy and safety in many tumor types; however, the clinical data on the treatment of hepatocellular carcinoma is rare."	9.22	Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Chen, C; Cheng, L; Fan, L; Hu, T; Lu, J; Lu, X; Ma, Y; Ni, B; Ou, S; Qi, F; Yi, X; Yu, L; Zhang, C; Zhao, C; Zheng, Z, 2016)
"The present pilot study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with interferon-beta (IFN-β) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)."	9.19	Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kora, S; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Tanaka, T; Tsuchiya, N; Yokoyama, K; Yoshimitsu, K; Yotsumoto, K, 2014)
"The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib."	9.17	Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013)
"To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin."	9.17	Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. ( Bai, Y; Bhudhisawasdi, V; Chao, Y; Fan, J; Kang, WK; Lee, JH; Lim, HY; Qin, S; Sun, Y; Thongprasert, S; Yang, TS; Zhou, Y, 2013)
"Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)."	9.16	Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012)
"To compare the efficacy of transcatheter arterial chemoembolization (TACE) using multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, and 5-furuorouracil: Multi group) with TACE using epirubicin (EP group) for hepatocellular carcinoma (HCC)."	9.16	Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. ( Ikoma, A; Kawai, N; Minamiguchi, H; Nakai, M; Nakata, K; Sahara, S; Sanda, H; Sato, M; Shirai, S; Sonomura, T; Tanaka, T, 2012)
"Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC)."	9.15	Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma. ( Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011)
"We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection."	9.15	Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011)
"This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC)."	9.15	Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. ( Arai, K; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Sunagozaka, H; Terashima, T; Ueda, T; Yamashita, T, 2011)
"This pilot phase II study was designed to determine the efficacy, toxicities, and biological activity of multiple hepatic arterial injections of recombinant adenovirus p53 (rAd-p53) and 5-fluorouracil (5-FU) after transcatheter arterial chemoembolization (TACE) when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC)."	9.14	Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. ( Chen, W; Liu, J; Tian, G; Zhou, JS, 2009)
"Although hepatic arterial infusion chemotherapy (HAIC) using low-dose 5-fluorouracil (5-FU) and cisplatin (low-dose FP) is commonly used for advanced hepatocellular carcinoma (HCC) with vascular invasion in Japan, few reports have investigated the efficacy and safety of this approach."	9.14	Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2010)
"To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)."	9.12	Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007)
"The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches."	9.12	Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007)
"The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)."	9.11	A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005)
"To evaluate the efficacy of combination chemotherapy with interferon-alpha (IFNalpha) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)."	9.11	Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. ( Enjoji, M; Kohjima, M; Kotoh, K; Miyagi, Y; Morizono, S; Nakamuta, M; Yoshimoto, T, 2005)
"We tested the efficacy of a systemic chemotherapy regimen combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF) in a cohort of patients with hepatocellular carcinoma (HCC) who could not be given surgical, intraarterial or percutaneous treatment."	9.10	Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). ( Boucher, E; Boudjema, K; Brissot, P; Corbinais, S; Raoul, JL, 2002)
"Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics."	9.10	Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003)
"In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated."	9.10	Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002)
"This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma."	9.10	Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002)
"A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma."	9.08	5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. ( Akman, S; Coluzzi, P; Doroshow, J; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Tetef, M, 1995)
"A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen."	8.77	[Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. ( Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C, 1989)
"Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy-HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad-HCC)."	8.31	Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. ( An, C; Guo, J; Li, C; Li, W; Lin, Y; Liu, Y; Qiao, Y; Zhou, M, 2023)
"Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown."	8.31	Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023)
"0NHAC-FUA) was fabricated through an amide condensation reaction to improve the therapeutic efficacy of 5-Fluorouracil (5-FU) in hepatocellular carcinoma (HCC)."	8.12	Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma. ( Chen, H; Chen, S; He, D; Li, Q; Liu, D; Ouyang, H; Pan, W; Wang, X; Xie, W; Yu, C, 2022)
"Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC)."	8.12	One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. ( Chen, M; He, M; Huang, Y; Kan, A; Lai, Z; Li, Q; Lin, X; Shi, M; Wei, W; Wen, D; Xu, L, 2022)
"Objective To investigate the effect of curcumin combined with 5-FU on autophagy and Yes-associated protein (YAP) expression in hepatocellular carcinoma cells."	8.02	[Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells]. ( Wang, X; Zhu, J, 2021)
" The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown."	8.02	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. ( Cao, Y; Cheng, JW; Fan, J; Hu, B; Huang, A; Huang, XW; Qiu, SJ; Sun, YF; Yang, XR; Zeng, HY; Zhang, X; Zhou, J, 2021)
" sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC)."	8.02	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. ( Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY, 2021)
"To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with a modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) regimen with that of transarterial chemoembolization as a locoregional treatment for patients with locally advanced hepatocellular carcinoma (HCC)."	8.02	Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. ( Deng, H; Han, X; He, M; Lai, J; Li, J; Li, S; Lyu, N; Shi, M; Wang, H; Zhao, M, 2021)
"The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)."	7.96	Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma. ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020)
"Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients."	7.96	Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020)
"To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)."	7.88	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018)
"To compare the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs."	7.88	Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. ( Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L, 2018)
"5-Fluorouracil (5-FU) has been widely applied to treat various types of cancers, including hepatocellular carcinoma (HCC)."	7.88	lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. ( Lin, X; Pan, C; Shi, L; Shi, Y; Wei, X; Wu, L; Zheng, J, 2018)
"We investigated the role of vitamin D (Vit D) alone and in combination with 5-fluorouracil (5-FU) in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) in rats."	7.88	Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats. ( Eissa, LA; El-Karef, A; El-Mesery, M; R Ebrahim, A, 2018)
"Argininosuccinate synthetase (ASS), a key enzyme to synthesize arginine is down regulated in many tumors including hepatocellular carcinoma (HCC)."	7.85	The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. ( Bhudhisawasdi, V; Li, YY; Navasumrit, P; Parnlob, V; Ruchirawat, M; Savaraj, N; Sricharunrat, T; Thongkum, A; Wangpaichitr, M; Wu, C, 2017)
"This study aimed to investigate the therapeutic effects of 5-fluorouracil (5-FU)-loaded nanobubbles irradiated with low-intensity, low-frequency ultrasound in nude mice with hepatocellular carcinoma (HCC)."	7.85	The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. ( Deng, H; He, C; Jing, Z; Li, H; Li, Q; Liu, C; Ma, W; Xie, J, 2017)
" Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism."	7.83	Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. ( Bi, T; Dai, W; Gao, Q; Liu, Y; Qian, L; Shen, G; Wang, G, 2016)
"To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)."	7.83	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016)
"This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China."	7.83	FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."	7.81	A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
" Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC)."	7.81	Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. ( Chen, S; Dong, L; Guo, W; He, X; Kong, Y; Li, J; Liu, C; Liu, W; Song, W; Wang, F; Yu, J; Yu, S; Zheng, Y, 2015)
" The present study is designed to explore the influence of CGA on the effects of 5-fluorouracil (5-FU) on human hepatocellular carcinoma cells (HepG2 and Hep3B)."	7.81	Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. ( Dong, L; Han, J; Hou, N; Li, J; Song, Y; Yan, Y, 2015)
"To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)."	7.81	Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015)
"Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)."	7.81	Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015)
"5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used for the treatment of hepatocellular carcinoma (HCC)."	7.80	The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Dong, Q; Gao, H; Jiang, H; Kong, J; Li, Z; Luo, X; Shi, B; Wang, H; Zhang, J, 2014)
"Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo."	7.80	Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014)
"To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)."	7.80	Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014)
"5-fluorouracil (5-FU)-based chemotherapy is widely used in the treatment of human hepatocellular carcinoma."	7.80	Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. ( Gao, S; Jiang, JX; Pan, YZ; Sun, CY; Yu, C, 2014)
" The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells."	7.80	Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014)
"Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment."	7.79	Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013)
"The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma."	7.79	Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. ( Abbruzzese, JL; Aloia, TA; Curley, SA; Hassabo, HM; Hassan, MM; Kaseb, AO; Lozano, RD; Patt, YZ; Roses, RE; Shindoh, J; Vauthey, JN; Zimmitti, G, 2013)
"Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable."	7.79	Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013)
"To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)."	7.79	Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013)
"A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease."	7.79	Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013)
" The aim of this study is to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A) poison etoposide in human hepatocellular carcinoma (HCC)."	7.79	MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. ( Feng, Y; Man, K; Tsao, SW; Wang, N; Zhang, Z; Zhu, M, 2013)
"We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)."	7.79	[Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013)
"Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)."	7.78	Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012)
"Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro."	7.78	Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. ( Chen, DR; Chen, YL; Cheng, CY; Chien, SY; Kuo, SJ; Su, CC, 2012)
"We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma."	7.78	Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012)
"Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols."	7.78	Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012)
"Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma."	7.78	Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012)
"There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy."	7.77	Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011)
"Although 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in various cancer including hepatocellular carcinoma (HCC), chemoresistance has precluded single use of 5-FU in clinical settings."	7.77	Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. ( Eguchi, Y; Hamajima, H; Iwane, S; Kawaguchi, Y; Mizuta, T; Ozaki, I; Takahashi, H; Yamamoto, K; Zhang, H, 2011)
"This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC)."	7.77	Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2011)
"Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)."	7.77	Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011)
"To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."	7.77	Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011)
"We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches."	7.77	Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"To investigate the apoptotic activities of casticin in hepatocellular carcinoma (HCC) cells and its molecular mechanisms."	7.77	Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. ( Cao, JG; Liu, F; Sheng, XF; Tian, L; Yang, J; Yang, Y, 2011)
"Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization."	7.77	Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011)
"We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)."	7.77	[A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011)
"To investigate the synergistic inhibitory effects of the combination of 5-fluorouracil (5-FU) with the natural flavanoid oroxylin A on human hepatocellular carcinoma cells HepG2 in vitro and on transplanted murine hepatoma 22 (H22) tumors in vivo and the preliminary mechanisms."	7.76	Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. ( Chen, Z; Guo, QL; Mu, R; Qi, Q; Wang, J; Yang, L; You, QD; Zhao, L; Zhao, Q, 2010)
"We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases."	7.76	Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010)
"The effects and mechanisms of action of beta-aescin and 5-fluorouracil (5-FU), alone and in combination, were studied in human hepatocellular carcinoma SMMC-7721 cells."	7.76	Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. ( Cao, L; Hu, Y; Ming, ZJ; Qiu, YH; Zhang, XG, 2010)
"Five fluorouracil (5-FU) is extensively used in the treatment of hepatocellular carcinoma (HCC)."	7.76	Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats. ( Abdel-Hamid, NM; Morsy, MA, 2010)
"We reported recently the clinical efficiency of interferon (IFN)-α/5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC)."	7.76	MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2010)
"Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)."	7.75	Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Matsubara, K; Matsuura, N; Monden, M; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Takemasa, I; Umeshita, K; Wada, H; Yoshioka, S, 2009)
"We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)."	7.75	Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009)
"Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC)."	7.75	Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. ( Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q, 2009)
"In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis."	7.75	Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009)
"The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC)."	7.75	Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. ( Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH, 2009)
"Epigallocatechin gallate (EGCG) from green tea could reverse multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) in vitro and in vivo."	7.74	[Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU]. ( Liang, G; Tang, HH; Zhou, M, 2008)
"We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy."	7.74	[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008)
"Several studies have reported the efficacy of combination therapy of interferon (IFN) alpha and 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)."	7.74	Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, T, 2007)
" The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis."	7.74	Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007)
"We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration."	7.74	Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007)
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil."	7.74	Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007)
"We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003."	7.74	[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007)
"We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor."	7.74	Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007)
"We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results."	7.74	Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007)
"Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis."	7.74	Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Hiramatsu, A; Ito, K; Jeong, SC; Kawakami, Y; Kodama, H; Miki, D; Shirakawa, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
"Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."	7.74	Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
"The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC)."	7.74	Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. ( Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2008)
"Several studies showed the effectiveness of combination therapy with IFN-alpha and 5-fluorouracil (5-FU) for advanced hepatocellular carcinoma."	7.73	Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. ( Damdinsuren, B; Dono, K; Eguchi, H; Hiraoka, N; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yamamoto, H; Yamamoto, T, 2005)
"We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches."	7.73	Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005)
"We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha)."	7.73	Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. ( Kita, K; Kuriyama, S; Kurokohchi, K; Masaki, T; Takaguchi, K, 2005)
"We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)."	7.73	[Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005)
"We investigated the antiproliferative effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) in combination on a hepatocellular carcinoma (HCC) cell line."	7.73	Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. ( Kojiro, M; Kojiro, S; Momosaki, S; Nishida, N; Ogasawara, S; Takemoto, Y; Yano, H, 2006)
"Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucidated."	7.73	The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. ( Hirano, K; Kojiro, M; Kuwano, M; Maruyama, Y; Oie, S; Ono, M; Terada, T; Ueno, T; Yamada, Y; Yano, H, 2006)
"To investigate the antitumor effect of interferon-alpha 2a (IFN-alpha2a) combined with capecitabine on hepatocellular carcinoma (HCC) in nude mice in relation to thymidine phosphorylase (TP) expression."	7.72	Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. ( Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J, 2004)
"We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival."	7.72	Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004)
"5-Fluorouracil (5-FU) as chemotherapy in cases of hepatocellular carcinoma (HCC), was found to initiate hepatotoxic injuries, ascites, leucopenia, thrombocytopenia and myelosupression that limit its use."	7.72	A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. ( El-Saadani, MA, 2004)
"The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine."	7.72	Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004)
"Previously we reported combined chemo-immunotherapy, using interferon (IFN)-alpha and 5-fluorouracil (5-FU) for patients with advanced hepatocellular carcinoma (HCC), and this regimen improved the prognosis."	7.72	Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. ( Aozasa, K; Dono, K; Hoshida, Y; Iizuka, N; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Tomita, Y; Umeshita, K; Yamamoto, S, 2004)
"Recently, combined chemotherapy with 5-fluorouracil (5-FU) and interferon (IFN)-alpha has been reported to show marked effects in patients with advanced hepatocellular carcinoma."	7.72	Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. ( Hoshida, Y; Kato, N; Kawabe, T; Moriyama, M; Omata, M; Otsuka, M; Yoshida, H, 2004)
"To investigate the effect of biochemical modulation on antitumor activity shown by the combination of 5-Fluorouracil (5-FU) and interferon-alpha (IFN-alpha), experimental therapy was performed on human hepatocellular carcinoma cell (HuH7, PLC/PLF/5) xenografts inoculated into nude mice, using 5-FU and IFN-alpha, either alone or in combination."	7.72	[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]. ( Arai, I; Dono, K; Jin, CD; Kishin, R; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Sakon, M; Umeshita, K; Xing, X; Yamamoto, T, 2004)
"We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)."	7.72	[Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004)
"Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)."	7.72	Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004)
"This study was designed to evaluate the efficacy of hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) for unresectable or recurrent hepatocellular carcinoma (HCC) with tumor thrombus of the trunk or first branches of the portal vein (PVTT)."	7.71	Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. ( Asahara, T; Haruta, N; Itamoto, T; Ito, K; Naito, A; Nakahara, H; Tashiro, H, 2002)
"We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously."	7.71	[A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002)
"To investigate the resistance mechanism of 5-fluorouracil (5-FU) in Bel(7402)/5-FU cells which was established in our lab by in vitro continuous stepwise exposure of human hepatocellular carcinoma (HCC) cell line Bel(7402) to 5-FU."	7.71	Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). ( Huang, M; Jin, J; Liu, GT; Wei, HL, 2002)
"A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)."	7.71	[A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001)
"The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)."	7.71	Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002)
"A 69-year-old female with unresectable hepatocellular carcinoma was treated with continuous arterial infusion of low-dose cisplatin (10 mg/body/day) and 5-fluorouracil (250 mg/body/day)."	7.71	[A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil]. ( Hasebe, Y; Hirano, K; Kobayashi, K; Kurihara, A; Nakazaki, H; Saito, N; Seo, A; Shirasaka, K; Takada, M; Takita, W; Tokura, N; Watanabe, M, 2002)
"The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs."	7.70	Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. ( Carrasco, CH; Charnsangavej, C; Cleary, K; Ellis, L; Hoque, A; Lozano, R; Patt, YZ; Roh, M, 1999)
"In order to assess the efficacy of repeated hepatic arterial infusion (HAI) therapy for advanced hepatocellular carcinoma, we administered HAI therapy using 5-fluorouracil, epirubicin and mitomycin C, with an implanted drug delivery system."	7.70	Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. ( Chiba, T; Ito, K; Kojima, K; Nakajima, N; Seno, H, 1999)
"Seven patients with postoperative recurrence of hepatocellular carcinoma (HCC) and four patients who underwent absolute non curative resection for HCC were treated with continuous arterial infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (250 mg/body/day)."	7.70	[Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 1999)
"Several clinical trials have demonstrated the effectiveness of combination therapy with 5-fluorouracil (5-FU) and IFN-alpha in colon cancer, hepatocellular carcinoma (HCC), and other malignancies."	7.70	Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. ( Dono, K; Eguchi, H; Kondo, M; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamamoto, H, 2000)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg."	7.67	[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma."	7.67	[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984)
"In a prospective clinical trial, 65 patients were studied in an investigation into the effects of the oral administration of 5-fluorouracil on resectable and non-resectable hepatocellular carcinoma."	7.67	Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma. ( , 1989)
"The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system."	7.67	Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989)
"HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels."	7.67	[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989)
" In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation."	7.67	[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987)
"An analysis is done of 40 evaluable patients treated with a combination of 5-Fluorouracil, adriamycin and mitomycin-C for primary hepatocellular carcinoma in Saudi Arabia."	7.67	Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. ( Abdel Satir, A; Al-Idrissi, HY; Al-Kasem, S; Al-Qurain, A; Ibrahim, EM; Satti, MB, 1985)
"The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)."	7.67	Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987)
"Twenty elderly patients with hepatocellular carcinoma were treated with 5-fluorouracil (5-FU) at a daily dose of 200-300 mg per os, and with a combination of 0."	7.66	[Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil]. ( Asano, K; Ejiri, T; Fujii, M; Matsuka, Y; Murakami, N, 1982)
"Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed."	6.90	All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019)
"Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited."	6.87	Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018)
"This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy."	6.80	Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015)
"Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15."	6.79	A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014)
"The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)."	6.77	Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012)
"Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection."	6.75	Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010)
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil."	6.73	Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007)
"Pravastatin was administered at a daily dose of 40 mg."	6.70	Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. ( Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E, 2001)
"Only a minority of patients with hepatocellular carcinoma (HCC) may benefit from curative treatments, whereas there is no standard therapy for the remaining patients."	6.70	A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Bruix, J; Castells, L; El-Hariry, I; Llovet, JM; Peachey, M; Ruff, P; Tassopoulos, N, 2001)
" 4' epidoxorubicin combined with 5-fluorouracil given intra-arterially is not superior to the intravenous therapy, but it may diminish systemic toxicity."	6.67	Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. ( Kajanti, M; Mäntylä, M; Pyrhönen, S; Rissanen, P, 1992)
"In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation."	6.50	Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. ( Gillmore, R; Goldstein, R; Mayer, A; Meyer, T; O'Donoghue, P; Thirlwell, C; Yu, D, 2014)
"The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor."	6.41	[Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002)
"Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer."	5.91	Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. ( Chen, H; Chen, J; Chen, Y; Li, A; Liu, J; Ma, L; Shao, H; Tang, Y, 2023)
"Primary liver hepatocellular carcinoma (HCC) is the third most deadly malignancy worldwide,in part, because it is often diagnosed at an advanced stage."	5.91	MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. ( Cai, C; He, X; Ji, S; Xu, M, 2023)
"5-Fluorouracil (5-FU) has been widely applied in treating cancers."	5.72	CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. ( Cheng, L; Li, Z; Pu, Y; Tu, L; Wang, X; Yan, D; Yu, J; Zheng, X, 2022)
"Cinobufagin is a natural product isolated from the traditional chinese medicine Chansu."	5.72	Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. ( Chen, Q; Li, H; Sun, Y; Tao, Y; Wang, A; Wu, Q; Yang, A; Yang, J; Zhang, J, 2022)
"To report the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and oxaliplatin (FOLFOX) in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI)."	5.69	Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. ( Cao, MR; Chen, HW; Cheng, Y; Deng, JD; Deng, M; Fang, CK; Guan, RG; Guo, RP; Guo, ZX; Huang, HK; Jiang, YC; Lei, QC; Li, JB; Li, Q; Li, SH; Lin, WP; Ling, YH; Lu, LH; Luo, R; Mei, J; Wang, QX; Wei, W; Wen, YH; Zhao, RC; Zheng, L; Zhong, C; Zou, JW, 2023)
"Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents."	5.62	Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. ( Chen, S; Guo, W; Huang, X; Li, T; Liu, Z; Wang, P; Wu, Y; Wu, Z; Xu, B; Yu, W, 2021)
"The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure."	5.56	Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. ( Chu, H; Dong, C; Hao, D; Li, R; Liu, J; Sun, R; Wang, L; Zhang, L; Zhang, Y; Zhao, B, 2020)
"5-Fluorouracil (5-Fu) is a widely used as an anticancer drug."	5.56	CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma. ( Ding, H; Wang, Y; Zhang, H, 2020)
" The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC."	5.56	Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. ( Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ, 2020)
" Since 5-FU is an irreversible inhibitor of thymidylate synthetase (TS), we investigated the interactions of let-7c with 5-FU at pharmacodynamic level."	5.56	Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. ( Jilek, JL; Tu, MJ; Yu, AM; Zhang, C, 2020)
"Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC)."	5.51	Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). ( Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M, 2022)
"However, its roles in hepatocellular carcinoma (HCC) cell stemness and chemotherapeutic sensitivity are never been revealed."	5.51	Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells. ( Chen, K; Chen, Z; Gao, T; Huang, J; Huang, M; Ou, M; Pan, D; Pan, J; Wei, H; Zhong, W, 2019)
"SIGNIFICANCE: It was reported that many hepatocellular carcinoma patients are resistance to 5-Fu."	5.51	Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. ( Fang, Z; Liu, Z; Miao, QR; Wang, Y; Yao, Y; Ye, M, 2019)
"5-Fluorouracil (5-FU) is a widely used antitumor drug."	5.51	Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. ( Cui, ZG; Feng, Q; Feril, LB; Inadera, H; Li, M; Sun, L; Zakki, SA, 2019)
"Baicalein is a flavonoid extracted from Radix Scutellariae with anti-HCC activity."	5.48	Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. ( Bie, B; Duan, B; Guo, Y; Huang, C; Li, J; Li, Z; Sun, J; Yang, J; Yang, S; Zhou, R, 2018)
"Cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) possess tumor-initiating, metastatic, and drug resistance properties."	5.43	Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. ( El-Boghdady, NA; El-Sayed, AM; Helmy, HS; Motawi, TK, 2016)
"Metformin plays an anti-proliferative role in tumor cells in many types of cancer."	5.43	Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016)
"Dioscin is a natural steroid saponin that presents in various plants."	5.43	Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3. ( Du, B; Liu, J; Tan, Y; Wu, Y; Wu, Z; Zeng, X; Zhang, G; Zhang, R; Zhang, W; Zhang, X; Zhao, Y, 2016)
"Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence."	5.42	MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large. ( Guo, R; Lei, X; Ma, J; Pan, X; Peng, C; Tang, H; Wang, T; Xiang, Q; Yang, X; Yin, J; Yu, J; Zu, X, 2015)
"Hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX-HAIC) has shown a strong anti-tumor effect in hepatocellular carcinoma in China."	5.41	Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. ( Du, Z; He, M; Kan, A; Lai, Z; Li, Q; Liu, S; Shen, J; Shi, M; Xu, L, 2023)
"A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies."	5.41	A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. ( Changou, CA; Chen, LT; Cheng, YC; Liu, S; Liu, SH; Luh, F; Shiah, HS; Yen, Y, 2021)
"The incidence of advanced hepatocellular carcinoma (HCC) is increasing worldwide, and its prognosis is extremely poor."	5.39	Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. ( Azumi, J; Gonda, K; Kanki, K; Mizuta, Y; Nagano, H; Sakabe, T; Shiota, G; Shomori, K; Tsuchiya, H; Wada, H; Yamada, D, 2013)
"The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus remains poor."	5.39	PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2013)
"Combination therapies may increase the antitumor effects and reduce the adverse effects for the treatment of hepatocellular carcinoma."	5.39	Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. ( Guo, QL; Lu, ZJ; Sha, YY; Yao, J; You, QD; Zhao, L; Zhao, Q; Zhu, BB, 2013)
"The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor."	5.39	Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013)
"Advanced hepatocellular carcinoma (HCC) with portal vein invasion or intrahepatic metastases has an unfavorable prognosis, even after curative hepatic resection."	5.39	Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. ( Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuo, K; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2013)
"The only drug that improves survival in hepatocellular carcinoma is sorafenib."	5.38	Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012)
"Baicalein treatment significantly inhibited tumor growth of HCC xenografts in mice."	5.38	Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. ( Huang, C; Le, XF; Li, J; Li, ZF; Liang, RR; Liu, PJ; Qi, JA; Wang, ZD; Yang, J; Zhang, S, 2012)
"The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy."	5.38	Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012)
"Flow cytometry and TUNEL assays in hepatic cancer cells showed that GC/5-FU was associated with higher rates of G0-G1 arrest and apoptosis than 5-FU."	5.38	5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. ( Chen, H; Cheng, M; Han, J; He, B; Li, Q; Wan, T; Wang, W; Xu, H; Yang, F; Ye, T; Zha, B; Zhu, W, 2012)
"The chemoresistance of human hepatocellular carcinoma (HCC) to cytotoxic drugs, especially intrinsic or acquired multidrug resistance (MDR), still remains a major challenge in the management of HCC."	5.38	Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. ( Cheng, BB; Fang, FF; Gu, W; Li, B; Ling, CQ, 2012)
"To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer."	5.38	[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012)
"There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus."	5.37	Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL."	5.37	Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011)
"Arsenic trioxide was added prior to a tyrosine kinase inhibitor or to a slightly modified PIAF regimen with capecitabine replacing 5-fluorouracil."	5.37	Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011)
"Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways."	5.36	Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B. ( Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB, 2010)
"d-Allose is a novel anti-tumor monosaccharide that causes cell growth inhibition, specifically of the cancer cells, by inducing the tumor suppressor gene thioredoxin interacting protein (TXNIP)."	5.35	Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7. ( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008)
": Patients with unresectable hepatocellular carcinoma (HCC) have limited treatment options."	5.35	Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. ( Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G, 2009)
" In this study, we evaluated the response to hepatic arterial infusion of 5-fluorouracil (5-FU) in combination with subcutaneous interferon (IFN)-alpha in patients with advanced HCC."	5.34	Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. ( Adachi, Y; Araki, J; Furjita, N; Horiike, S; Itani, T; Iwasa, M; Kaito, M; Kobayashi, Y; Konishi, M; Kuroda, M; Mifuji, R; Tanaka, H; Urawa, N; Yamamoto, M, 2007)
"5-fluorouracil (5-FU) is a basic agent used in chemotherapy."	5.34	Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue. ( Ebara, M; Nomura, F; Saisho, H; Shimada, H; Sunaga, M; Tomonaga, T; Yoshikawa, M, 2007)
"Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2."	5.34	Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007)
"Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor."	5.33	[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C]. ( Ahn, SH; Cho, KB; Choi, JS; Chung, WJ; Hwang, JS; Hwang, JY; Jang, BK; Kim, GC; Kim, YH; Kwon, JH; Kwon, KM; Park, KS, 2005)
"Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation."	5.33	5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005)
"For 15 patients with advanced hepatocellular carcinoma using a same protocol, the response rate of this therapy was 33."	5.33	[Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports]. ( Bazarragchaa, D; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Murakami, T; Nagano, H; Nakamura, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H; Yoshioka, S, 2005)
"Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis."	5.33	[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006)
"The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal."	5.33	[A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006)
"A syngeneic rat model of hepatocellular carcinoma was used."	5.32	[Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats]. ( Jiang, GP; Li, MW; Xie, HY; Yang, FC; Zeng, QL; Zheng, SS, 2003)
"Five human hepatoma cell lines (Hep3B, HepG2, HuH7, PLC/PRF/5 and Chang) were used."	5.32	The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. ( Iwasaki, T; Kogure, T; Shimosegawa, T; Ueno, Y, 2004)
"The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein."	5.32	Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. ( Dono, K; Ishii, S; Kato, K; Kurokawa, Y; Matoba, R; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takemasa, I; Ueno, N; Umeshita, K, 2004)
"The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor."	5.31	Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002)
"Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit."	5.30	Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. ( Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R, 2019)
"Fifteen patients with advanced hepatocellular carcinoma were treated by hepatic arterial infusion (HAI)."	5.28	[Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU]. ( Akimura, R; Fujii, N; Ikami, I; Kanehira, J; Kimura, T; Midorikawa, H; Nakamura, Y; Sasaki, T; Tarusawa, K; Yodono, H, 1990)
"In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior."	5.27	Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. ( Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K, 2018)
"Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma."	5.26	Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979)
"The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)."	5.24	A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017)
"Raltitrexed has shown efficacy and safety in many tumor types; however, the clinical data on the treatment of hepatocellular carcinoma is rare."	5.22	Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Chen, C; Cheng, L; Fan, L; Hu, T; Lu, J; Lu, X; Ma, Y; Ni, B; Ou, S; Qi, F; Yi, X; Yu, L; Zhang, C; Zhao, C; Zheng, Z, 2016)
"To compare the efficacy and safety of chemoembolization alone or chemoembolization combined with hepatic arterial infusion chemotherapy (HAIC), including oxaliplatin (OXA), 5-fluorouracil (5-FU) and folinic acid (CF), in inoperable hepatocellular carcinoma (HCC) without distant metastasis."	5.20	Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. ( Chen, H; Gao, S; Guo, JH; Liu, P; Xu, HF; Yang, RJ; Zhang, PJ; Zhu, X, 2015)
"The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advanced hepatocellular carcinoma (HCC)."	5.19	Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. ( Bai, Y; Cheng, Y; Fan, J; Jian, Z; Li, J; Liang, H; Liang, J; Liang, L; Qin, S; Rau, KM; Shen, L; Sun, Y; Wu, G; Yang, TS; Zhang, Y, 2014)
" Because previous studies showed that long-term telbivudine treatment improved renal function in chronic hepatitis B virus (HBV) infected patients, we conducted a case-control study to evaluate the clinical outcome of telbivudine preemptive therapy in HBV-related advanced HCC patients treated by combination chemotherapy comprising 5-fluorouracil, mitoxantrone and cisplatin (FMP)."	5.19	Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study. ( Chang, ML; Chen, YC; Chien, RN; Hsu, CW; Lin, CL; Yeh, C; Yeh, CT, 2014)
"The present pilot study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with interferon-beta (IFN-β) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)."	5.19	Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kora, S; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Tanaka, T; Tsuchiya, N; Yokoyama, K; Yoshimitsu, K; Yotsumoto, K, 2014)
"The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib."	5.17	Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013)
"To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin."	5.17	Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. ( Bai, Y; Bhudhisawasdi, V; Chao, Y; Fan, J; Kang, WK; Lee, JH; Lim, HY; Qin, S; Sun, Y; Thongprasert, S; Yang, TS; Zhou, Y, 2013)
"Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)."	5.16	Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012)
"To compare the efficacy of transcatheter arterial chemoembolization (TACE) using multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, and 5-furuorouracil: Multi group) with TACE using epirubicin (EP group) for hepatocellular carcinoma (HCC)."	5.16	Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. ( Ikoma, A; Kawai, N; Minamiguchi, H; Nakai, M; Nakata, K; Sahara, S; Sanda, H; Sato, M; Shirai, S; Sonomura, T; Tanaka, T, 2012)
"Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC)."	5.15	Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma. ( Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011)
"We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection."	5.15	Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011)
"This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC)."	5.15	Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. ( Arai, K; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Sunagozaka, H; Terashima, T; Ueda, T; Yamashita, T, 2011)
"This pilot phase II study was designed to determine the efficacy, toxicities, and biological activity of multiple hepatic arterial injections of recombinant adenovirus p53 (rAd-p53) and 5-fluorouracil (5-FU) after transcatheter arterial chemoembolization (TACE) when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC)."	5.14	Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. ( Chen, W; Liu, J; Tian, G; Zhou, JS, 2009)
"Although hepatic arterial infusion chemotherapy (HAIC) using low-dose 5-fluorouracil (5-FU) and cisplatin (low-dose FP) is commonly used for advanced hepatocellular carcinoma (HCC) with vascular invasion in Japan, few reports have investigated the efficacy and safety of this approach."	5.14	Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2010)
"To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)."	5.12	Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007)
"The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches."	5.12	Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007)
"The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)."	5.11	A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005)
"To evaluate the efficacy of combination chemotherapy with interferon-alpha (IFNalpha) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)."	5.11	Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. ( Enjoji, M; Kohjima, M; Kotoh, K; Miyagi, Y; Morizono, S; Nakamuta, M; Yoshimoto, T, 2005)
"Pegylated liposomal doxorubicin-based combination chemotherapy with capecitabine or gemcitabine was not effective as salvage therapy in advanced hepatocellular carcinoma."	5.11	Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. ( Bai, LY; Chen, PM; Poh, SB, 2005)
"We tested the efficacy of a systemic chemotherapy regimen combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF) in a cohort of patients with hepatocellular carcinoma (HCC) who could not be given surgical, intraarterial or percutaneous treatment."	5.10	Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). ( Boucher, E; Boudjema, K; Brissot, P; Corbinais, S; Raoul, JL, 2002)
"Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics."	5.10	Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003)
"In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated."	5.10	Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002)
"This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma."	5.10	Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002)
"To determine surgical resectability, event-free survival (EFS), and toxicity in children with hepatocellular carcinoma (HCC) randomized to treatment with either cisplatin (CDDP), vincristine, and fluorouracil (regimen A) or CDDP and continuous-infusion doxorubicin (regimen B)."	5.10	Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. ( Bowman, LC; Castleberry, RP; Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; Katzenstein, HM; Krailo, MD; Liu-Mares, W; Malogolowkin, MH; Newman, K; Ortega, JA; Quinn, JJ; Reynolds, M; Sensel, MG, 2002)
"The purpose of this Phase II study was to determine the response rate, the toxicity, and the effect on survival of the combination of cisplatin, doxorubicin, 5-fluorouracil, and alpha-IFN (PIAF) in advanced unresectable hepatocellular carcinoma."	5.09	Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. ( Chan, AT; Ho, SK; Johnson, PJ; Lau, WY; Leung, NW; Leung, TW; Liew, CT; Mok, TS; Patt, YZ; Tang, AM; Yeo, W; Yu, SC, 1999)
"A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma."	5.08	5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. ( Akman, S; Coluzzi, P; Doroshow, J; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Tetef, M, 1995)
"A Phase II clinical trial was conducted to evaluate the efficacy of intravenous fluorouracil (5-FU) and subcutaneous recombinant interferon-alpha-2b (rIFN-alpha-2b) in the treatment of hepatocellular carcinoma (HCC) and to define factors that might be predictive of a response to treatment."	5.07	Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. ( Charnsangavej, C; Cleary, K; Fischer, H; Levin, B; Noonan, CA; Patt, YZ; Pazdur, R; Roh, M; Smith, R; Yoffe, B, 1993)
"We conducted a randomized, controlled trial comparing 5-fluorouracil (5-FU) with or without biological response modifiers (BRMs) as a maintenance therapy for hepatocellular carcinoma (HCC) after treatment with percutaneous ethanol injection (PEI), transcatheter arterial embolization (TAE) or arterial infusion of antitumor agents (AI)."	5.07	Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. ( Fukuda, S; Moriya, N; Sakata, Y; Sasaki, D; Suto, T; Watanabe, Y; Yoshida, Y, 1994)
"Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy)."	5.07	Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. ( Desai, DC; Desouza, LJ; Dhir, V; Dinshaw, KA; Jagannath, P; Mohandas, KM; Nagral, A; Sharma, V; Swaroop, VS, 1992)
"In a prospective clinical trial, 39 patients with advanced hepatocellular carcinoma were randomized to receive either Adriamycin (20 patients) or a combination of 5-fluorouracil, methotrexate, cyclophosphamide, and vincristine (19 patients)."	5.05	Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. ( Choi, TK; Lee, NW; Wong, J, 1984)
"Twenty-one patients with biopsy-proven hepatocellular carcinoma were treated with oral or intravenous 5-Fluorouracil according to a randomized treatment schedule."	5.04	5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases. ( Bateman, JR; Durkin, WJ; Link, JS; Paroly, WS; Peters, RL, 1977)
"We report a case of long-term survival of a patient who received low-dose 5-fluorouracil and cisplatin (FP) systemic chemotherapy and underwent partial resection of the lung for a tumor thrombus in the inferior caval vein (IVC) and multiple lung metastases from recurrent hepatocellular carcinoma (HCC)."	4.90	[A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma]. ( Akasu, I; Fukushima, G; Kataoka, H; Kondo, K; Magata, H; Marutsuka, H; Nakamura, K; Otani, K; Sato, Y; Yano, K; Yonei, A, 2014)
"A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen."	4.77	[Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. ( Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C, 1989)
"Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy-HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad-HCC)."	4.31	Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. ( An, C; Guo, J; Li, C; Li, W; Lin, Y; Liu, Y; Qiao, Y; Zhou, M, 2023)
"Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown."	4.31	Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023)
"0NHAC-FUA) was fabricated through an amide condensation reaction to improve the therapeutic efficacy of 5-Fluorouracil (5-FU) in hepatocellular carcinoma (HCC)."	4.12	Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma. ( Chen, H; Chen, S; He, D; Li, Q; Liu, D; Ouyang, H; Pan, W; Wang, X; Xie, W; Yu, C, 2022)
"Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC)."	4.12	One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. ( Chen, M; He, M; Huang, Y; Kan, A; Lai, Z; Li, Q; Lin, X; Shi, M; Wei, W; Wen, D; Xu, L, 2022)
"Objective To investigate the effect of curcumin combined with 5-FU on autophagy and Yes-associated protein (YAP) expression in hepatocellular carcinoma cells."	4.02	[Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells]. ( Wang, X; Zhu, J, 2021)
"FOLFOX is a combinational regimen of folinic acid (FnA, FOL), fluorouracil (5-Fu, F) and oxaliplatin (OxP, OX), and has been long considered as the standard treatment of colorectal cancer (CRC) and hepatocellular carcinoma (HCC)."	4.02	Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. ( Guo, J; Huang, L; Liu, Y; Sun, D; Yu, Z; Zou, Y, 2021)
" The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown."	4.02	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. ( Cao, Y; Cheng, JW; Fan, J; Hu, B; Huang, A; Huang, XW; Qiu, SJ; Sun, YF; Yang, XR; Zeng, HY; Zhang, X; Zhou, J, 2021)
"This study aimed to assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with modified FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) as an alternative treatment option in advanced hepatocellular carcinoma (HCC) patients with failed or unsuitability for transarterial chemoembolization (TACE)."	4.02	Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. ( Chen, MP; Chen, RX; Chen, Y; Ge, NL; Hsu, SJ; Luo, JF; Ren, ZG; Wang, Y; Wang, YH; Xu, X; Yin, X; Zhang, L; Zhao, ZY, 2021)
"This study aimed to utilize cholesterol conjugation of 5-fluorouracil (5-FUC) and liposomal formulas to enhance the partitioning of 5-FU into low density lipoprotein (LDL) to target hepatocellular carcinoma (HCC)."	4.02	Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition. ( Al Meanazel, AT; Al Meanazel, OT; Alanazi, FK; Alanazi, SA; Alomrani, AH; Badran, MM; Elzayat, E; Harisa, GI, 2021)
" sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC)."	4.02	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. ( Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY, 2021)
"To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with a modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) regimen with that of transarterial chemoembolization as a locoregional treatment for patients with locally advanced hepatocellular carcinoma (HCC)."	4.02	Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. ( Deng, H; Han, X; He, M; Lai, J; Li, J; Li, S; Lyu, N; Shi, M; Wang, H; Zhao, M, 2021)
"The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)."	3.96	Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma. ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020)
"Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients."	3.96	Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020)
"Currently, 5-fluorouracil (5-FU) resistance became a major obstacle to its clinical use for patients with hepatocellular carcinoma (HCC)."	3.91	H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA. ( Li, F; Li, Z; Wang, J; Wei, N; Wu, N; Zhang, H, 2019)
" In this study, a biotin-/lactobionic acid-modified poly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly(ethylene glycol) (BLPP) copolymer was synthesized, and curcumin- and 5-fluorouracil-loaded nanoparticles (BLPPNPs/C + F) were prepared to enhance the treatment of hepatocellular carcinoma."	3.91	Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma. ( Gao, X; Ji, Y; Jian, X; Li, Z; Liu, Z; Ni, W; Sun, S; Wu, L, 2019)
"Bile salts (GCDA) promoted the proliferation of hepatocellular carcinoma (HCC) cells (HepG2 and QGY-7703), and GCDA treatment reduced the chemosensitivity of 5-fluorouracil (5FU) in HepG2 and QGY-7703 cells."	3.91	Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma. ( Jin, X; Li, X; Liao, M; Wang, C; Xiao, X; Yang, M; Zhang, Y; Zhao, J, 2019)
"To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)."	3.88	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018)
"To compare the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs."	3.88	Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. ( Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L, 2018)
"5-Fluorouracil (5-FU) has been widely applied to treat various types of cancers, including hepatocellular carcinoma (HCC)."	3.88	lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. ( Lin, X; Pan, C; Shi, L; Shi, Y; Wei, X; Wu, L; Zheng, J, 2018)
"We investigated the role of vitamin D (Vit D) alone and in combination with 5-fluorouracil (5-FU) in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) in rats."	3.88	Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats. ( Eissa, LA; El-Karef, A; El-Mesery, M; R Ebrahim, A, 2018)
" We found that the downregulation or complete depletion of SND1 enhanced the apoptosis levels of HepG2 and SMMC-7721 cells upon stimulation with 5-Fu (5-fluorouracil), a chemotherapeutic drug for HCC (hepatocellular carcinoma)."	3.88	SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma. ( Cui, X; Gao, X; Qian, B; Ren, Y; Su, C; Yang, J; Yao, X; Yao, Z; Zhao, C, 2018)
"Argininosuccinate synthetase (ASS), a key enzyme to synthesize arginine is down regulated in many tumors including hepatocellular carcinoma (HCC)."	3.85	The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. ( Bhudhisawasdi, V; Li, YY; Navasumrit, P; Parnlob, V; Ruchirawat, M; Savaraj, N; Sricharunrat, T; Thongkum, A; Wangpaichitr, M; Wu, C, 2017)
"This study aimed to investigate the therapeutic effects of 5-fluorouracil (5-FU)-loaded nanobubbles irradiated with low-intensity, low-frequency ultrasound in nude mice with hepatocellular carcinoma (HCC)."	3.85	The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. ( Deng, H; He, C; Jing, Z; Li, H; Li, Q; Liu, C; Ma, W; Xie, J, 2017)
" Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism."	3.83	Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. ( Bi, T; Dai, W; Gao, Q; Liu, Y; Qian, L; Shen, G; Wang, G, 2016)
"Three human hepatocellular carcinoma cell lines--HepG2, Hep3B and HuH-7--were pre- and post-treated with doxorubicin, 5-fluorouracil (5-FU) and cisplatin."	3.83	Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence. ( Farmer, RW; Li, Y; Martin, RC; Yang, Y, 2016)
"To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)."	3.83	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016)
"This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China."	3.83	FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."	3.81	A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
" Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC)."	3.81	Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. ( Chen, S; Dong, L; Guo, W; He, X; Kong, Y; Li, J; Liu, C; Liu, W; Song, W; Wang, F; Yu, J; Yu, S; Zheng, Y, 2015)
" Herein, we report that NPs conjugated with antibody against GRP78 (mAb GRP78-NPs) inhibit the adhesion, invasion, and metastasis of hepatocellular carcinoma (HCC) and promote drug delivery of 5-fluorouracil into GRP78 high-expressed human hepatocellular carcinoma cells."	3.81	Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78. ( Li, H; Liu, L; Shi, Y; Su, C; Su, R; Wang, G; Zhao, L, 2015)
" The present study is designed to explore the influence of CGA on the effects of 5-fluorouracil (5-FU) on human hepatocellular carcinoma cells (HepG2 and Hep3B)."	3.81	Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. ( Dong, L; Han, J; Hou, N; Li, J; Song, Y; Yan, Y, 2015)
"To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)."	3.81	Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015)
"Seventy-three patients with liver cirrhosis (LC) and advanced HCC (aHCC) received hepatic arterial infusion chemotherapy (HAIC: leucovorin (LV) at 12 mg/h, cisplatin (CDDP) at 10 mg/h and 5-fluorouracil (5-FU) at 250 mg/22 h) via the proper hepatic artery every 5 days for 4 weeks using a catheter connected to a subcutaneous drug delivery system."	3.81	VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy. ( Matsui, D; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y, 2015)
"Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)."	3.81	Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015)
"Sorafenib is a systemic chemotherapeutic agent for advanced hepatocellular carcinoma (HCC)."	3.81	Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling. ( Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, M; Lee, S; Park, SY; Yoon, JH, 2015)
" Here, we report the effect of an APN inhibitor 4cc in enhancing sensitivity of hepatocellular carcinoma (HCC) cell lines and xenograft model in response to 5-fluorouracil (5-FU) in vivo and in vitro."	3.81	Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition. ( Dai, G; Duan, Y; Shi, LH; Sun, ZP; Wang, XJ; Xu, WF; Zhang, J; Zhang, XR, 2015)
"Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC)."	3.80	A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. ( Chang, ML; Hsu, CL; Hung, CF; Liang, KH; Lin, CC; Yeh, CT, 2014)
"5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used for the treatment of hepatocellular carcinoma (HCC)."	3.80	The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Dong, Q; Gao, H; Jiang, H; Kong, J; Li, Z; Luo, X; Shi, B; Wang, H; Zhang, J, 2014)
"Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo."	3.80	Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014)
"To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)."	3.80	Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014)
"In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5-FU) were developed for targeted delivery to hepatocellular carcinoma."	3.80	Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles. ( Dangi, R; Gulbake, A; Hurkat, P; Jain, A; Jain, SK; Shilpi, S, 2014)
"5-fluorouracil (5-FU)-based chemotherapy is widely used in the treatment of human hepatocellular carcinoma."	3.80	Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. ( Gao, S; Jiang, JX; Pan, YZ; Sun, CY; Yu, C, 2014)
" The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells."	3.80	Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014)
"Children with hepatocellular carcinoma (HCC) were treated on a prospective, randomized trial and were then analyzed to determine whether children with the fibrolamellar (FL) histologic variant of HCC have a more favorable presentation, increased surgical resectability, greater response to therapy, and improved outcome compared with children who have typical HCC."	3.80	Fibrolamellar hepatocellular carcinoma in children and adolescents. ( Bowman, LC; Castleberry, RP; Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; Katzenstein, HM; Krailo, MD; Malogolowkin, MH; Newman, K; Ortega, JA; Qu, W; Quinn, JJ; Reynolds, M; Sensel, MG, 2003)
"Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment."	3.79	Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013)
"The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma."	3.79	Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. ( Abbruzzese, JL; Aloia, TA; Curley, SA; Hassabo, HM; Hassan, MM; Kaseb, AO; Lozano, RD; Patt, YZ; Roses, RE; Shindoh, J; Vauthey, JN; Zimmitti, G, 2013)
"Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable."	3.79	Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013)
"To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)."	3.79	Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013)
" Our study found that the expression of miR-27a was down-regulated in the multidrug-resistant hepatocellular carcinoma cell line BEL-7402/5-fluorouracil (BEL/5-FU) compared with its parental BEL-7402 cell line, while the MDR1/P-glycoprotein expression was elevated."	3.79	MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. ( Chen, Z; Hu, T; Huang, C; Li, J; Lv, X; Ma, T; Xu, T; Zhang, L, 2013)
"To explore the potential of iodized linoleic acid (ILA) and its 5-fluoro-deoxyuridine ester (IFU) to inhibit hepatocellular carcinoma (HCC) cells in vitro and tumors in vivo."	3.79	[A preliminary study of the inhibitive efficacy of iodized linoleic acid and its fluorodeoxyuridine ester in hepatocellular cancer]. ( Dai, ZY; Jiang, YB; Kuang, CX; Li, KC; Zeng, XY, 2013)
"A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease."	3.79	Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013)
" The aim of this study is to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A) poison etoposide in human hepatocellular carcinoma (HCC)."	3.79	MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. ( Feng, Y; Man, K; Tsao, SW; Wang, N; Zhang, Z; Zhu, M, 2013)
"Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits."	3.79	Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. ( Lee, HJ; Lee, SH; Oh, MJ, 2013)
"We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)."	3.79	[Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013)
"Acquired resistance to 5-fluorouracil (5-FU) is a serious therapeutic obstacle in advanced hepatocellular carcinoma (HCC) patients."	3.79	The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression. ( Duan, X; Wang, J; Ye, W; Zhang, M; Zhou, S, 2013)
"Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)."	3.78	Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012)
" Swiss mice inoculated with hepatoma HepA(22) or sarcoma 180 (S(180)) cells were treated with ShD or 5-fluorouracil (5Fu)."	3.78	Shikonin derivatives protect immune organs from damage and promote immune responses in vivo in tumour-bearing mice. ( BaoJie, G; GuangZhi, Y; LiHua, L; Long, S; Wei, X; Yang, Z; YanYong, H; YingLi, W, 2012)
"Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro."	3.78	Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. ( Chen, DR; Chen, YL; Cheng, CY; Chien, SY; Kuo, SJ; Su, CC, 2012)
"5-Fluorouracil (5-FU) chemotherapy is the first choice treatment for advanced hepatocellular carcinoma (HCC), and resistance is the major obstacle to successful treatment."	3.78	Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. ( Kasamatsu, A; Kobayashi, E; Sakurada, T; Sato, N; Sunaga, M; Tanzawa, H; Uchibori, K; Ueda, S; Uzawa, K; Yokota, S; Yoshikawa, M, 2012)
"The aim of the present study was to design a targeted delivery system of 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)."	3.78	Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma. ( Hassanzadeh, F; Khadem, M; Sadeghi, H; Varshosaz, J, 2012)
"We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma."	3.78	Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012)
"Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols."	3.78	Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012)
"Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma."	3.78	Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012)
"There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy."	3.77	Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011)
"Although 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in various cancer including hepatocellular carcinoma (HCC), chemoresistance has precluded single use of 5-FU in clinical settings."	3.77	Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. ( Eguchi, Y; Hamajima, H; Iwane, S; Kawaguchi, Y; Mizuta, T; Ozaki, I; Takahashi, H; Yamamoto, K; Zhang, H, 2011)
"This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC)."	3.77	Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2011)
" We investigated the therapeutic efficacies of metronomic S-1, an oral 5-fluorouracil prodrug, and vandetanib, an epidermal growth factor receptor and vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, in models of hepatocellular carcinoma (HCC)."	3.77	Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. ( Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H, 2011)
"Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)."	3.77	Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011)
"To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."	3.77	Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011)
"Cytotoxic activity of artemisinin and derivatives in the presence and absence of holo-transferrin and expression of genes involved in resistance of cancer cells were investigated in human cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines in vitro."	3.77	Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines. ( Chaijaroenkul, W; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2011)
"We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches."	3.77	Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin (HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular carcinoma (HCC)."	3.77	Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results. ( Jung, G; Kim, BH; Kim, JS; Kim, NY; Lee, KJ; Park, SJ; Park, YM; Yeon, JW; Yun, HK, 2011)
"To investigate the apoptotic activities of casticin in hepatocellular carcinoma (HCC) cells and its molecular mechanisms."	3.77	Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. ( Cao, JG; Liu, F; Sheng, XF; Tian, L; Yang, J; Yang, Y, 2011)
"Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization."	3.77	Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011)
"We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)."	3.77	[A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011)
"To investigate the synergistic inhibitory effects of the combination of 5-fluorouracil (5-FU) with the natural flavanoid oroxylin A on human hepatocellular carcinoma cells HepG2 in vitro and on transplanted murine hepatoma 22 (H22) tumors in vivo and the preliminary mechanisms."	3.76	Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. ( Chen, Z; Guo, QL; Mu, R; Qi, Q; Wang, J; Yang, L; You, QD; Zhao, L; Zhao, Q, 2010)
"We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases."	3.76	Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010)
"The effects and mechanisms of action of beta-aescin and 5-fluorouracil (5-FU), alone and in combination, were studied in human hepatocellular carcinoma SMMC-7721 cells."	3.76	Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. ( Cao, L; Hu, Y; Ming, ZJ; Qiu, YH; Zhang, XG, 2010)
"Five fluorouracil (5-FU) is extensively used in the treatment of hepatocellular carcinoma (HCC)."	3.76	Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats. ( Abdel-Hamid, NM; Morsy, MA, 2010)
" However, it has also been reported that 5-fluorouracil (5-FU) exacerbates liver damage in patients with liver cirrhosis (LC)."	3.76	Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma. ( Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Matsui, T; Momiyama, K; Nagai, H; Shinohara, M; Shizawa, K; Sumino, Y; Wakui, N; Watanabe, M, 2010)
" Here, we provide genetic evidence that ATM kinase activity is required to trigger 5-FU- and neocarzinostatin-dependent cFLIP(L) and cFLIP(S) down-regulation, which in turn sensitize hepatocellular carcinoma (HCC) cell lines to TRAIL."	3.76	ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis. ( Barilà, D; Giaccari, D; Mingardi, M; Santini, S; Stagni, V, 2010)
"We reported recently the clinical efficiency of interferon (IFN)-α/5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC)."	3.76	MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2010)
"We report a case of advanced hepatocellular carcinoma (HCC) successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic administration of interferon (IFN)-α and trans-arterial infusion (TAI) therapy of cisplatin (CDDP)."	3.76	[A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi]. ( Doki, Y; Eguchi, H; Hashimoto, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H, 2010)
"Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)."	3.75	Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Matsubara, K; Matsuura, N; Monden, M; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Takemasa, I; Umeshita, K; Wada, H; Yoshioka, S, 2009)
"We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)."	3.75	Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009)
"Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC)."	3.75	Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. ( Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q, 2009)
"The combination therapy of interferon (IFN)-alpha and 5-fluorouracil (5-FU) improved the prognosis of the patients with hepatocellular carcinoma (HCC)."	3.75	Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H; Yamamoto, H, 2009)
"In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis."	3.75	Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009)
"The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC)."	3.75	Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. ( Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH, 2009)
"Epigallocatechin gallate (EGCG) from green tea could reverse multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) in vitro and in vivo."	3.74	[Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU]. ( Liang, G; Tang, HH; Zhou, M, 2008)
"We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy."	3.74	[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008)
"Several studies have reported the efficacy of combination therapy of interferon (IFN) alpha and 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)."	3.74	Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, T, 2007)
" The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis."	3.74	Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007)
"We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration."	3.74	Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007)
"To evaluate the effect of combined antisense oligonucleotides targeting midkine (MK-AS) and chemotherapeutic drugs [cisplatin(DDP), 5-fluorouracil (5-FU) and adriamycin (ADM)] on inhibition of HepG2 cell proliferation, and to analyze the efficacy of MK-AS used in combined ADM in in situ human hepatocellular carcinoma (HCC) model."	3.74	Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma. ( Dai, LC; He, JF; Lu, YL; Ping, JL; Wang, X; Yao, X, 2007)
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil."	3.74	Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007)
"We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003."	3.74	[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007)
"We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor."	3.74	Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007)
"We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results."	3.74	Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007)
"To investigate the multicellular resistance of human hepatocellular carcinoma HepG2 cells in three-dimensional culture to delisheng, 5-fluorouracil and adriamycin, and the possible molecular mechanisms of delisheng."	3.74	Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture. ( Cui, J; Guo, YH; Nan, KJ; Tian, T; Wang, L; Zhao, N, 2007)
"Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis."	3.74	Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Hiramatsu, A; Ito, K; Jeong, SC; Kawakami, Y; Kodama, H; Miki, D; Shirakawa, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
"Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."	3.74	Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
" Here, we examined the role p53 plays in the antitumour effect of combination treatment with pegylated interferon (PEG-IFN)-alpha and 5-fluorouracil (5-FU), which has been shown to effectively treat advanced hepatocellular carcinoma (HCC)."	3.74	Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. ( Fukuta, N; Hagiwara, S; Hayakawa, S; Kimura, M; Kudo, M; Munakata, H; Nagashima, M; Nakatani, T; Sakaguchi, Y, 2007)
"To observe changes of sensitivity to 5'-deoxy-5-fluorouridine (5'-dFUrd), and 5-fluorouracil (5-FU) in SMMC-7721 hepatocellular carcinoma cells by interferon alpha (IFN-alpha), and its relationship with the expression of thymidine phosphorylase (TP)."	3.74	[Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5'-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase]. ( Fan, J; Liu, YK; Sun, RX; Tang, ZY; Xiao, YS; Ye, SL; Zhao, Y; Zhou, J, 2007)
"The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC)."	3.74	Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. ( Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2008)
"Several studies showed the effectiveness of combination therapy with IFN-alpha and 5-fluorouracil (5-FU) for advanced hepatocellular carcinoma."	3.73	Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. ( Damdinsuren, B; Dono, K; Eguchi, H; Hiraoka, N; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yamamoto, H; Yamamoto, T, 2005)
"The effect of tacrolimus (FK506) and 5-fluorouracil (5-FU) on hepatocellular carcinoma remains elusive."	3.73	Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721. ( Cao, XW; Ding, GS; Fu, ZR, 2005)
"We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches."	3.73	Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005)
"We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha)."	3.73	Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. ( Kita, K; Kuriyama, S; Kurokohchi, K; Masaki, T; Takaguchi, K, 2005)
"We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)."	3.73	[Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005)
"This study was designed to reveal whether the apoptosis induced in human hepatocellular carcinoma (HCC) cell lines by 5-fluorouracil (5-FU) could be enhanced by transfecting Bcl-2 small interfering RNA (siRNA)."	3.73	Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. ( Arai, M; Imazeki, F; Kanda, T; Saisho, H; Yokosuka, O, 2005)
"We investigated the antiproliferative effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) in combination on a hepatocellular carcinoma (HCC) cell line."	3.73	Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. ( Kojiro, M; Kojiro, S; Momosaki, S; Nishida, N; Ogasawara, S; Takemoto, Y; Yano, H, 2006)
"Interferon (IFN) combined with 5-Fluorouracil (5-FU) treatment has recently been reported to show beneficial effects in patients with advanced hepatocellular carcinoma."	3.73	Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines. ( Iwasaki, Y; Koike, K; Sakaguchi, K; Shiraha, H; Shiratori, Y; Suzuki, M; Takaki, A; Tatsukawa, M, 2006)
"Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucidated."	3.73	The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. ( Hirano, K; Kojiro, M; Kuwano, M; Maruyama, Y; Oie, S; Ono, M; Terada, T; Ueno, T; Yamada, Y; Yano, H, 2006)
" Anti-proliferative effects of single treatment with IFN-alpha subtypes or 5-fluorouracil (FU), and of combined treatment with each IFN-alpha subtype and 5-FU were examined on three hepatocellular carcinoma cell lines, HepG2, HLE and PLC/PRF/5."	3.73	Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells. ( Arai, N; Ariyasu, H; Ariyasu, T; Fujioka, N; Fukuda, S; Ikeda, M; Ikegami, H; Kurimoto, M; Ohta, T; Tanimoto, T; Yamamoto, S, 2006)
"The use of 5-fluorouracil, topotecan, or gemcitabine was tested for enhancement of the effects of low dose rate (LDR) irradiation in an in vitro model for hepatocellular carcinoma."	3.73	Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma. ( de Gelder, V; De Ridder, L; De Vos, F; Lambert, B; Slegers, G; Thierens, H; Van de Wiele, C, 2006)
"This study was to investigate the effect of capecitabine on recurrent tumor and metastasis after curative resection of liver cancer, xenograft of a highly metastatic human hepatocellular carcinoma (HCC) tumor (LCI-D20), with special reference to the expression of platelet-derived endothelial cell growth factor (PD-ECGF)."	3.72	Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. ( Fan, J; Ji, Y; Li, XM; Liu, YK; Shi, YH; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Ye, SL; Zhou, J, 2003)
"To study the effect of wild type (wt) p53 gene transfection on drug resistant human hepatocellular carcinoma (HCC) cells induced by 5-Fluorouracil (5-FU)."	3.72	Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells. ( Li, YX; Lin, ZB; Tan, HR, 2004)
"We report a case in which low-dose FP (5-fluorouracil/cisplatin, 5-FU/CDDP) therapy was remarkably effective for stage IVB advanced hepatocellular carcinoma (HCC) with lung and bone metastases."	3.72	[Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases]. ( Fujio, N; Fukuda, Y; Koyama, I; Mayumi, K; Osugi, H; Takatori, H; Terakura, M; Tsukazaki, T; Tsukazaki, Y, 2004)
"To investigate the antitumor effect of interferon-alpha 2a (IFN-alpha2a) combined with capecitabine on hepatocellular carcinoma (HCC) in nude mice in relation to thymidine phosphorylase (TP) expression."	3.72	Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. ( Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J, 2004)
"We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival."	3.72	Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004)
"5-Fluorouracil (5-FU) as chemotherapy in cases of hepatocellular carcinoma (HCC), was found to initiate hepatotoxic injuries, ascites, leucopenia, thrombocytopenia and myelosupression that limit its use."	3.72	A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. ( El-Saadani, MA, 2004)
"The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine."	3.72	Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004)
"Previously we reported combined chemo-immunotherapy, using interferon (IFN)-alpha and 5-fluorouracil (5-FU) for patients with advanced hepatocellular carcinoma (HCC), and this regimen improved the prognosis."	3.72	Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. ( Aozasa, K; Dono, K; Hoshida, Y; Iizuka, N; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Tomita, Y; Umeshita, K; Yamamoto, S, 2004)
"Recently, combined chemotherapy with 5-fluorouracil (5-FU) and interferon (IFN)-alpha has been reported to show marked effects in patients with advanced hepatocellular carcinoma."	3.72	Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. ( Hoshida, Y; Kato, N; Kawabe, T; Moriyama, M; Omata, M; Otsuka, M; Yoshida, H, 2004)
"To investigate the effect of biochemical modulation on antitumor activity shown by the combination of 5-Fluorouracil (5-FU) and interferon-alpha (IFN-alpha), experimental therapy was performed on human hepatocellular carcinoma cell (HuH7, PLC/PLF/5) xenografts inoculated into nude mice, using 5-FU and IFN-alpha, either alone or in combination."	3.72	[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]. ( Arai, I; Dono, K; Jin, CD; Kishin, R; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Sakon, M; Umeshita, K; Xing, X; Yamamoto, T, 2004)
"We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)."	3.72	[Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004)
"Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)."	3.72	Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004)
" In 25 patients with HCC, in vitro chemosensitivity to 5-fluorouracil (5-FU), epirubicin (EPI), and cisplatin (CDDP) was examined by CD-DST, and 5-FU, EPI, and paclitaxel (PTX) were examined in 38 patients with breast cancer."	3.72	[In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures]. ( Abumiya, K; Kamachi, H; Kamiyama, N; Kamiyama, T; Khor, LW; Kobayashi, H; Kurauchi, N; Matsushita, M; Nakagawa, T; Nakajima, H; Nakanishi, K; Taguchi, K; Takahashi, H; Takahashi, M; Todo, S; Tsukahara, M; Watanabe, K, 2004)
"This study was designed to evaluate the efficacy of hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) for unresectable or recurrent hepatocellular carcinoma (HCC) with tumor thrombus of the trunk or first branches of the portal vein (PVTT)."	3.71	Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. ( Asahara, T; Haruta, N; Itamoto, T; Ito, K; Naito, A; Nakahara, H; Tashiro, H, 2002)
"We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously."	3.71	[A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002)
"To investigate the resistance mechanism of 5-fluorouracil (5-FU) in Bel(7402)/5-FU cells which was established in our lab by in vitro continuous stepwise exposure of human hepatocellular carcinoma (HCC) cell line Bel(7402) to 5-FU."	3.71	Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). ( Huang, M; Jin, J; Liu, GT; Wei, HL, 2002)
"A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)."	3.71	[A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001)
"The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)."	3.71	Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002)
"A 69-year-old female with unresectable hepatocellular carcinoma was treated with continuous arterial infusion of low-dose cisplatin (10 mg/body/day) and 5-fluorouracil (250 mg/body/day)."	3.71	[A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil]. ( Hasebe, Y; Hirano, K; Kobayashi, K; Kurihara, A; Nakazaki, H; Saito, N; Seo, A; Shirasaka, K; Takada, M; Takita, W; Tokura, N; Watanabe, M, 2002)
"Between 1990 and 1997, 227 patients with hepatocellular carcinoma were treated by intrahepatic arterial injection of a Lipiodol-Epirubicin-Mitomycin C emulsion followed by intermittent hepatic artery infusion of Epirubicin, Mitomycin C and 5-FU, employing an implantable subcutaneous infusion port."	3.70	[Transcatheter oily chemoembolization and intermittent hepatic artery infusion chemotherapy in the management of advanced hepatocellular carcinoma]. ( An, M; Hamada, E; Ikawa, M; Matsumoto, Y; Miura, T; Murata, M; Nakasato, S; Takagi, S; Terakado, H; Watanabe, K, 1998)
"The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs."	3.70	Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. ( Carrasco, CH; Charnsangavej, C; Cleary, K; Ellis, L; Hoque, A; Lozano, R; Patt, YZ; Roh, M, 1999)
"In order to assess the efficacy of repeated hepatic arterial infusion (HAI) therapy for advanced hepatocellular carcinoma, we administered HAI therapy using 5-fluorouracil, epirubicin and mitomycin C, with an implanted drug delivery system."	3.70	Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. ( Chiba, T; Ito, K; Kojima, K; Nakajima, N; Seno, H, 1999)
"Seven patients with postoperative recurrence of hepatocellular carcinoma (HCC) and four patients who underwent absolute non curative resection for HCC were treated with continuous arterial infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (250 mg/body/day)."	3.70	[Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 1999)
"Several clinical trials have demonstrated the effectiveness of combination therapy with 5-fluorouracil (5-FU) and IFN-alpha in colon cancer, hepatocellular carcinoma (HCC), and other malignancies."	3.70	Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. ( Dono, K; Eguchi, H; Kondo, M; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamamoto, H, 2000)
"Continuous systemic infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (500 mg/body/day) was performed for advanced hepatocellular carcinoma (HCC) after hepatectomy with diffuse lung metastases and multiple intrahepatic metastases."	3.70	[Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 2000)
"A patient with advanced unresectable fibrolamellar hepatocellular carcinoma is reported, who was treated with cisplatinum, epirubicin and 5-fluorouracil combination chemotherapy."	3.69	Fibrolamellar hepatocellular carcinoma responsive to platinum-based combination chemotherapy. ( Bower, M; Habib, N; Newlands, ES, 1996)
"Arterial infusion chemotherapy of EPF (etoposide, cisplatin, and 5-fluorouracil) or EAP (etoposide, Adriamycin, and cisplatin) was carried out in 28 cases of advanced hepatocellular carcinoma (HCC) between January 1988 and December 1990, and assessment was made of the anticancer efficacy of each treatment method."	3.68	Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. ( Midorikawa, H; Saito, Y; Sasaki, T; Takekawa, SD; Tarusawa, K; Yodono, H, 1992)
" Regarding HAI, transcatheter hepatic arterial embolization (TAE) was applied in two cases (hepatocellular carcinoma: 1; metastasis: 1) and 5-fluorouracil (continuous) combined with leucovorin (one shot) therapy (LV + 5-FU) was given to one metastatic case."	3.68	[Bile duct necrosis and hepatic necrosis following hepatic arterial infusion chemotherapy]. ( Arai, K; Iwasaki, Y; Kitamura, M; Miyashita, K; Mori, T; Okamoto, A, 1991)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg."	3.67	[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma."	3.67	[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984)
"An investigation was carried out into the effects of lipiodol-transcatheter arterial chemoembolization (L-TACE) therapy on hepatocellular carcinoma (HCC) and metastatic liver cancer, as well as the effects of oral 5-fluorouracil administration after L-TACE."	3.67	Effects of transcatheter arterial chemoembolization with oral chemotherapy on hepatic neoplasms. ( Hashimoto, N; Inoue, J; Kawai, S; Makino, M; Masuzawa, M; Mikuriya, S; Oda, T; Shimamura, Y; Takahashi, A; Yumoto, Y, 1989)
"In a prospective clinical trial, 65 patients were studied in an investigation into the effects of the oral administration of 5-fluorouracil on resectable and non-resectable hepatocellular carcinoma."	3.67	Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma. ( , 1989)
"The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system."	3.67	Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989)
"UFT was administered preoperatively in 20 cases of primary hepatocellular carcinoma, and tegafur, 5-fluorouracil (5-FU), uracil, total thymidylate synthase (TS) and free TS in blood and liver tissue were determined."	3.67	[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis]. ( Ito, Y; Matsuoka, S; Misawa, K; Nagafuchi, E; Nakajima, Y; Ogasawara, K; Sato, N; Uchino, J; Une, Y, 1989)
"HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels."	3.67	[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989)
" In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation."	3.67	[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987)
"Before proceeding with a resection of a hepatocellular carcinoma (HCC) in patients, the concentrations of 5-FU and 1-Hexylcarbamoyl-5-fluorouracil (HCFU) have been measured in the serum, the liver, and in the cancer tissue after an oral administration of HCFU (300 mg)."	3.67	[5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration]. ( Suenaga, M, 1988)
"Fifty-four patients with unresectable malignant liver tumors (14 of hepatocellular carcinoma, 40 of metastasis to the liver from gastric or colo-rectal cancer) were treated with intra-hepato-arterial (IHA) injections of cis-diamminedichloroplatinum (II) (CDDP) plus 5-fluorouracil (5-FU)."	3.67	[Hepatic arterial chemotherapy combined with hyperthermia or arterial embolization in unresectable liver tumor]. ( Hamazoe, R; Inoue, Y; Ishiguro, M; Koga, S; Maeda, M; Murakami, A; Sawata, T; Shimizu, N; Shimizu, T; Wakatsuki, T, 1988)
"An analysis is done of 40 evaluable patients treated with a combination of 5-Fluorouracil, adriamycin and mitomycin-C for primary hepatocellular carcinoma in Saudi Arabia."	3.67	Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. ( Abdel Satir, A; Al-Idrissi, HY; Al-Kasem, S; Al-Qurain, A; Ibrahim, EM; Satti, MB, 1985)
"The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)."	3.67	Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987)
" An improvement of the chemotherapy of hepatocellular carcinoma with adriamycin or 5-fluorouracil and a reduction of side effects has been achieved by intra-arterial administration of the drugs."	3.66	[Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)]. ( Gerok, W; Holstege, A; Keppler, D; Pausch, J, 1981)
"The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors."	3.66	[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983)
"Twenty elderly patients with hepatocellular carcinoma were treated with 5-fluorouracil (5-FU) at a daily dose of 200-300 mg per os, and with a combination of 0."	3.66	[Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil]. ( Asano, K; Ejiri, T; Fujii, M; Matsuka, Y; Murakami, N, 1982)
"Tegafur fine granule preparation orally administered to the patients with primary hepatoma and liver cirrhosis, and the concentration of tegafur and 5-fluorouracil in the blood were determined."	3.66	[Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer]. ( Hattori, M; Horiike, N; Kanaoka, M; Ohta, Y; Onji, M; Yamashita, Y; Yoshida, T, 1982)
"Nine patients with extensive bilateral hepatic metastases of colorectal cancer were treated with hepatic artery ligation and continuous infusion of 5-fluorouracil (5-FU)."	3.65	Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. ( Eilber, FR; Holmes, EC; Morton, DL; Ramming, KP; Sparks, FC, 1976)
"The case of a young man with hypogonadism, who was treated for five years withmethyltestosterone and who developed hepatocellular carcinoma, is discussed."	3.65	Hepatocellular carcinoma in association with androgen therapy. ( Goodman, MA; Laden, AM, 1977)
"The majority of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage."	3.30	Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. ( Cheng, S; Guo, W; Huo, L; Jiang, D; Lau, WY; Liu, C; Mao, F; Shi, J; Sun, J; Zhang, F; Zhou, L, 2023)
"Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development."	3.01	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. ( Iwamoto, H; Kawaguchi, T; Niizeki, T; Shimose, S; Shirono, T, 2023)
" We conducted this phase Ib/II study to assess the safety and efficacy of anti-PD-1 antibody camrelizumab in combination with FOLFOX4 for treatment-naive advanced hepatocellular carcinoma (aHCC)."	3.01	Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. ( Chen, Z; Li, H; Liu, Y; Meng, Z; Qin, S; Ren, Z; Wang, L; Xiong, J; Zhang, X; Zou, J, 2021)
"Arginine is an important nutrient for hepatocellular carcinoma (HCC)."	3.01	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. ( Abou-Alfa, GK; Akce, M; Bomalaski, JS; Chen, YY; Cohen, SA; El Dika, I; Feng, YH; Harding, JJ; Ho, CL; Huang, WT; Johnston, A; Lee, DW; Lim, HY; Meyer, T; O'Reilly, EM; Qin, S; Ryoo, BY; Sarker, D; Tan, B; Yang, TS; Yen, CJ, 2021)
"Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed."	2.90	All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019)
"Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited."	2.87	Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018)
"This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy."	2.80	Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015)
"Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15."	2.79	A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014)
"To compare the effect of radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of 3 - 5 cm hepatocellular carcinoma (HCC)."	2.78	[Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience]. ( Bao, LW; Jiang, XF; Jin, XJ; Lin, JJ; Lu, LJ; Wu, W, 2013)
"The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)."	2.77	Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012)
"Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection."	2.75	Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010)
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil."	2.73	Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007)
"To evaluate the effect of tamoxifen (TAM) combined with a somatostatin analogue, octretide (OCT) on advanced liver cancer and whether tamoxifen combined with OCT is superior to regular chemotherapeutic agents 5-Fu and mitomycin C (MMC)."	2.71	Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. ( Chen, JW; Huo, YC; Pan, DY; Qiao, JG; Shi, HA; Zhou, YK, 2003)
" Pharmacokinetic parameters were studied during the first cycle of dose levels 1 and 2 (500 mg/m2."	2.71	A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. ( Brown, G; Chak, K; Chan, AT; Johnson, P; Leung, TW; Mok, TS; Moyses, C; Wong, H; Yeo, W, 2004)
"Over 80% of hepatocellular carcinoma (HCC) patients are HBV carriers; however, the incidence of HBV reactivation during CT has not been well-reported."	2.71	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. ( Chan, AT; Chan, PS; Ho, WM; Johnson, PJ; Lam, KC; Leung, TW; Ma, B; Mo, FK; Mok, TS; Wong, WL; Yeo, W; Zee, B, 2004)
"Thirty-eight unresectable small hepatocellular carcinoma patients with diameter	2.71	[Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xia, JL; Yang, BW; Yie, SL; Zhang, BH, 2004)
"The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor."	2.70	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. ( Ando, E; Fukumori, K; Kuromatsu, R; Okuda, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y; Yutani, S, 2002)
"Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis."	2.70	[Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis]. ( Ahn, SH; Cheong, JY; Chon, CY; Han, KH; Kim, JS; Lee, DY; Moon, YM; Seong, JS; Youn, YH, 2002)
"Pravastatin was administered at a daily dose of 40 mg."	2.70	Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. ( Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E, 2001)
"Only a minority of patients with hepatocellular carcinoma (HCC) may benefit from curative treatments, whereas there is no standard therapy for the remaining patients."	2.70	A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Bruix, J; Castells, L; El-Hariry, I; Llovet, JM; Peachey, M; Ruff, P; Tassopoulos, N, 2001)
"The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy."	2.69	[Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999)
"Four cases of gigantic hepatocellular carcinoma, considered by surgeons to be inoperable, were treated with repeated transcatheter chemoembolization (TOCE) until the serum alfafetoprotein reduced to normal or less than half of the original level or until the tumor reduced to less than half of the original size documented by CT scan and angiogram."	2.69	Gigantic hepatocellular carcinoma, treated by transcatheter oily chemoembolization (TOCE) and wedge hepatic resection. ( Eurvilaichit, C; Kanjanapitak, A; Leopairut, J, 2000)
"2 of the 7 (29%) patients with hepatoma responded."	2.68	Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. ( Cunningham, D; Ellis, PA; Hickish, T; Hill, A; Nicolson, M; Norman, A; O'Brien, ME, 1995)
"Unresectable hepatocellular carcinoma is related to a poor prognosis."	2.68	Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. ( Colleoni, M; Liessi, G; Manente, P; Mastrapasqua, G; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G, 1997)
" 4' epidoxorubicin combined with 5-fluorouracil given intra-arterially is not superior to the intravenous therapy, but it may diminish systemic toxicity."	2.67	Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. ( Kajanti, M; Mäntylä, M; Pyrhönen, S; Rissanen, P, 1992)
"Hepatocellular carcinoma is known to have a doubling time of approximately 41 days."	2.66	194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. ( Fishman, EK; Guse, C; Klein, JL; Leibel, SA; Leichner, PK; Order, SE; Stillwagon, GB, 1989)
"Forty-seven patients with hepatocellular cancer were treated in a randomised trial comparing adriamycin + VM 26 + 5-Fluorouracil (5-FU) to mAMSA + VM 26 + 5-FU."	2.66	Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil. ( Bezwoda, WR; Derman, DP; Kew, M; Weaving, A, 1987)
"Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2."	2.55	Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. ( Kong, L; Kou, P; Shao, W; Wang, H; Yu, J; Zhang, J; Zhang, Y; Zhu, H, 2017)
"Primary liver cancer, mainly consisting of hepatocellular carcinoma (HCC), is one of common malignancies worldwide, and prevalent among the Chinese population."	2.53	Progress in systemic therapy of advanced hepatocellular carcinoma. ( Gong, XL; Qin, SK, 2016)
"In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation."	2.50	Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. ( Gillmore, R; Goldstein, R; Mayer, A; Meyer, T; O'Donoghue, P; Thirlwell, C; Yu, D, 2014)
"The majority of primary liver cancer is hepatocellular carcinoma (HCC)."	2.44	Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. ( Nagai, H; Sumino, Y, 2008)
"Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity."	2.44	[Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007)
"Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting."	2.44	[Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007)
"Patients with hepatocellular carcinoma (HCC) frequently show early recurrence even after hepatic resection and local ablation therapy."	2.42	[Chemotherapy for hepatocellular carcinoma]. ( Ikeda, M; Okusaka, T; Ueno, H, 2004)
"The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor."	2.41	[Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002)
"Hepatocellular carcinoma is a rapidly fatal disease in most patients."	2.37	Medical treatment of hepatocellular carcinoma. ( Friedman, M; Nerenstone, S, 1987)
"Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%."	2.36	[Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978)
"Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer."	1.91	Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. ( Chen, H; Chen, J; Chen, Y; Li, A; Liu, J; Ma, L; Shao, H; Tang, Y, 2023)
"Molecular targeted therapy combined with immunotherapy significantly improves the prognosis of patients with advanced liver cancer."	1.91	Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study. ( Gao, W; Guo, Z; Li, H; Li, M; Liu, C; Liu, D; Mu, H; Si, T; Xing, W; Yang, X; Yu, H; Zhang, K; Zhang, W; Zou, Q, 2023)
"Primary liver hepatocellular carcinoma (HCC) is the third most deadly malignancy worldwide,in part, because it is often diagnosed at an advanced stage."	1.91	MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. ( Cai, C; He, X; Ji, S; Xu, M, 2023)
" The primary endpoint was overall survival (OS), while the secondary endpoints were progression-free survival and adverse effects."	1.72	Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study. ( Hibi, T; Ishii, M; Itano, O; Itano, S; Iwamoto, H, 2022)
"5-Fluorouracil (5-FU) has been widely applied in treating cancers."	1.72	CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. ( Cheng, L; Li, Z; Pu, Y; Tu, L; Wang, X; Yan, D; Yu, J; Zheng, X, 2022)
"Cinobufagin is a natural product isolated from the traditional chinese medicine Chansu."	1.72	Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. ( Chen, Q; Li, H; Sun, Y; Tao, Y; Wang, A; Wu, Q; Yang, A; Yang, J; Zhang, J, 2022)
"Fibrolamellar carcinoma (FLC) is a rare liver cancer that predominantly affects younger patients without a history of liver disease."	1.72	Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report. ( Akce, M; Draper, A; El-Rayes, B; Guadagno, J; Kang, S; Magliocca, J; Pectasides, M; Roccaro, G; Sellers, M; Zheng, W, 2022)
" We analysed the pharmacokinetic profile of the less toxic photoform ("ring-closed" dithienylethene) of the compound in tumors, plasma, and healthy liver."	1.72	Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data. ( Afonin, S; Babii, O; Borysko, P; Dovbynchuk, T; Dziubenko, N; Garmanchuk, LV; Gorbach, O; Khranovska, N; Komarov, IV; Kuznietsova, H; Schober, T; Shtanova, LY; Tolstanova, G; Ulrich, AS; Veselsky, SP; Yanchuk, PI, 2022)
"Hazard ratios for overall survival and disease progression were 0."	1.72	A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study. ( Cheng, S; Gu, J; Jiang, D; Lau, WY; Liu, C; Mao, F; Shen, L; Shi, J; Sun, J; Wang, N; Zhou, L, 2022)
"Our results provide preliminary evidence that HAIC based on FOLFIRI regimen is efficient and safe in some patients progressing after previous treatment."	1.72	The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. ( Chen, Y; Huang, P; Huang, X; Shi, G; Sun, Q; Yang, G; Zhou, Y, 2022)
"To evaluate the clinical efficacy of targeted therapy and immunotherapy combined with hepatic arterial infusion chemotherapy (HAIC) of FOLFOX and lipiodol embolization in the treatment of unresectable hepatocellular carcinoma."	1.72	Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma. ( Chen, D; Chen, Y; Hu, XL; Huang, DB; Li, XQ; Lin, ZP; Xu, SX; Zhang, J; Zhong, H; Zou, XG, 2022)
"Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents."	1.62	Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. ( Chen, S; Guo, W; Huang, X; Li, T; Liu, Z; Wang, P; Wu, Y; Wu, Z; Xu, B; Yu, W, 2021)
"5-Fluorouracil (5-FU) is a broad-spectrum anticancer drug, but its clinical application is limited due to drug resistance and toxic side effects."	1.56	Preparation and evaluation of phytantriol liquid crystal as a liquid embolic agent. ( Fang, X; Shen, A, 2020)
"The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure."	1.56	Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. ( Chu, H; Dong, C; Hao, D; Li, R; Liu, J; Sun, R; Wang, L; Zhang, L; Zhang, Y; Zhao, B, 2020)
"Liver cancer is a major threat to human life and health, and chemotherapy has been the standard non-surgical treatment for liver cancer."	1.56	Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux. ( Dong, C; Jiang, K; Li, R; Lv, J; Sun, R; Wang, L; Wang, Q; Yin, Z; Zhang, J; Zhou, Y, 2020)
"5-Fluorouracil (5-Fu) is a widely used as an anticancer drug."	1.56	CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma. ( Ding, H; Wang, Y; Zhang, H, 2020)
"Efficient hepatocellular carcinoma (HCC) therapy remains a significant challenge due to the unsatisfactory targeting efficiency of nanoparticles (NPs) with either a passive targeting or a single active targeting property."	1.56	Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy ( He, DX; Huang, C; Huang, W; Liu, Y; Long, J; Tan, XW; Tang, S; Wei, H; Xiang, Y; Yu, CY; Zhou, Y, 2020)
"IORT using the INTRABEAM radiation system combined with portal vein infusion chemotherapy is promising for select patients with PVTT."	1.56	INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. ( Han, M; He, Y; Liang, H; Shao, Z; Song, X, 2020)
" The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC."	1.56	Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. ( Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ, 2020)
" Since 5-FU is an irreversible inhibitor of thymidylate synthetase (TS), we investigated the interactions of let-7c with 5-FU at pharmacodynamic level."	1.56	Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. ( Jilek, JL; Tu, MJ; Yu, AM; Zhang, C, 2020)
"This paper discussed the synergistic anti-tumor effect of Shuangdan Capsules combined with 5-fluorouracil(5-FU) on human liver cancer cell line Huh-7 and tumor bearing mice."	1.56	[Study on synergistic anti-tumor effect of Shuangdan Capsules combined with 5-FU on hepatocellular carcinoma cells Huh-7 and xenograft mice]. ( Chen, XW; Ding, WB; Ning, Q; Song, J; Xia, Z; Zhou, XW, 2020)
"However, its roles in hepatocellular carcinoma (HCC) cell stemness and chemotherapeutic sensitivity are never been revealed."	1.51	Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells. ( Chen, K; Chen, Z; Gao, T; Huang, J; Huang, M; Ou, M; Pan, D; Pan, J; Wei, H; Zhong, W, 2019)
"Patients with advanced hepatocellular carcinoma (HCC) have a poor oncologic outcome."	1.51	Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. ( Cho, CW; Lee, BH; Lee, DS; Yun, SS, 2019)
"SIGNIFICANCE: It was reported that many hepatocellular carcinoma patients are resistance to 5-Fu."	1.51	Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. ( Fang, Z; Liu, Z; Miao, QR; Wang, Y; Yao, Y; Ye, M, 2019)
"5-Fluorouracil (5-FU) is a widely used antitumor drug."	1.51	Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. ( Cui, ZG; Feng, Q; Feril, LB; Inadera, H; Li, M; Sun, L; Zakki, SA, 2019)
"We reported a patient survived more than 7years after undergoing hepatectomy accompanied by tumor thrombectomy in the main trunk of the portal vein after preoperative hepatic arterial chemotherapy for hepatocellular carcinoma combined with tumor thrombus in the main portal vein."	1.48	[A Case of a Long-Term Survivor Who Underwent Surgical Intervention for Hepatocellular Carcinoma Combined with Tumor Thrombus in the Main Trunkof the Portal Vein]. ( Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R, 2018)
"Baicalein is a flavonoid extracted from Radix Scutellariae with anti-HCC activity."	1.48	Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. ( Bie, B; Duan, B; Guo, Y; Huang, C; Li, J; Li, Z; Sun, J; Yang, J; Yang, S; Zhou, R, 2018)
"The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus in the major portal vein (PV) is extremely poor."	1.48	Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap ( Hatano, E; Uemoto, S; Yamamoto, M; Yamaue, H, 2018)
"This study investigated the anti-hepatoma activity of different extracts from A."	1.46	Studies on anti-hepatoma activity of Annona squamosa L. pericarp extract. ( Cao, YZ; Chen, JW; Chen, Y; Chen, YY; Li, FQ; Li, X; Lu, JH; Peng, CX; Zhu, XL, 2017)
"Liver fibrosis is characterized by the progressive accumulation of extracellular matrix (ECM) and is a strong predictor of hepatocellular carcinoma (HCC) development and progression."	1.46	A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells. ( Fukumitsu, K; Ishii, T; Katayama, H; Kawai, T; Kita, S; Kojima, H; Minami, T; Miyauchi, Y; Ogiso, S; Sasaki, N; Uemoto, S; Yamaoka, R; Yasuchika, K; Yasuda, K; Yoshitoshi-Uebayashi, EY, 2017)
" In the CCRT group, concurrent hepatic arterial infusion chemotherapy with 5-fluorouracil was delivered at a dosage of 500 mg/d during the first and last 5 days of radiation therapy (median, 45 Gy)."	1.46	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. ( Ahn, SH; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Seong, J; Song, JE; Song, K; Won, JY, 2017)
"Cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) possess tumor-initiating, metastatic, and drug resistance properties."	1.43	Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. ( El-Boghdady, NA; El-Sayed, AM; Helmy, HS; Motawi, TK, 2016)
"The treatment efficacy of unresectable hepatocellular carcinoma (HCC) is still not promising."	1.43	Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. ( Bao, Y; Dai, Y; Dong, X; Feng, W; Shen, J; Tang, C; Zhang, J; Zheng, Y, 2016)
"Metformin plays an anti-proliferative role in tumor cells in many types of cancer."	1.43	Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016)
"Locally advanced hepatocellular carcinoma (HCC) with portal vein thrombosis carries a 1-year survival rate <10%."	1.43	Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. ( Choi, GH; Choi, JS; Han, DH; Han, KH; Joo, DJ; Kim, MS; Kim, SI; Park, YN; Seong, J, 2016)
"BACKGROUND Hepatocellular carcinoma (HCC) causes many deaths worldwide every year, especially in Asia."	1.43	Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma. ( He, B; Hu, X; Liu, J; Liu, S; Wang, H, 2016)
"Dioscin is a natural steroid saponin that presents in various plants."	1.43	Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3. ( Du, B; Liu, J; Tan, Y; Wu, Y; Wu, Z; Zeng, X; Zhang, G; Zhang, R; Zhang, W; Zhang, X; Zhao, Y, 2016)
"Liver cancer is one of the most drug-resistant cancer types, and cancer stem cells are related to drug resistance."	1.42	JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. ( Ahn, YH; Jee, HG; Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, JH; Lee, M; Park, SY; Yoon, JH; Yu, SJ, 2015)
"A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007."	1.42	Hepatic arterial infusion in hepatocellular carcinoma: a single center experience. ( Dvorak, J; Ferko, A; Kamaradova, K; Krajina, A; Melichar, B, 2015)
"The clinicopathological parameters and adverse effects were similar between the 2 groups (P > 0."	1.42	Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. ( Burns, M; Hong, Y; Lei, X; Li, JL; Li, QL; Li, YG; Liu, C; Liu, HC; Liu, JS; Qiu, XX; Wang, XH; Wu, QF; Xia, M; Xiao, H; Xu, RC; Zhu, HZ; Zuo, CH, 2015)
"To investigate the cooperative effect of Bifidobacteria lipoteichoic acid (BLTA) combined with 5-fluorouracil on tumor cells growth and apoptosis in mice bearing H22."	1.42	Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis. ( Guo, B; Wang, Y; Xie, N, 2015)
" The purpose of this study was to determine the treatment effect of irradiation in combination with hepatic arterial infusion chemotherapy (HAIC) for these patients."	1.42	Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. ( Kanazawa, S; Katsui, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Onishi, H; Sakaguchi, K; Shiraha, H; Takaki, A; Takeuchi, Y; Wada, N; Yamamoto, K; Yasunaka, T, 2015)
"Nineteen hepatic cancer cell lines, 50 cases of adjacent tissue and 149 cases of HCC samples were employed."	1.42	Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU. ( Brock, MV; Guo, M; Herman, JG; Li, X; Liang, P; Tao, Q; Yu, J, 2015)
"Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence."	1.42	MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large. ( Guo, R; Lei, X; Ma, J; Pan, X; Peng, C; Tang, H; Wang, T; Xiang, Q; Yang, X; Yin, J; Yu, J; Zu, X, 2015)
" Compared with either agent alone, a low dose of Dox combined with eAFP-VISA-BikDD induced better antitumor effect and prolonged longer survival of mice in two orthotopic liver cancer xenograft models."	1.42	Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. ( Chen, HY; Dai, HY; Hung, MC; Lai, WC; Li, LY, 2015)
"Cucurbitacin B is a plant-derived tetracyclic triterpenoid, which has been used for a variety of cancers, especially human hepatoma."	1.42	Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells. ( Chen, D; Hu, H; Huang, Z; Qiao, M; Sun, Y; Zhang, J; Zhao, X; Zhou, J, 2015)
"Luteolin may inhibit tumor angiogenesis and tumor cell proliferation by down-regulation of LFA- 3 and PCNA and up-regulation of ICAM-1 in tumor tissue of tumor-bearing mice, thereby achieving its anti-tumor effect."	1.42	Effect of luteolin on gene expression in mouse H22 hepatoma cells. ( Bao, LD; Gan, HM; Guo, HP; Niu, JX; Ren, JJ, 2015)
"HUVEC and human hepatoma cells (MHCC97H) were cultured, respectively, and then the MHCC97H cells were co-cultured with conditioned medium from HUVEC (EC-CM) with Transwell system."	1.42	[Effect of Conditioned Medium from Endothelial Cells on Cancer Stem Cell Phenotype of Hepatoma Cells]. ( Feng, C; Luo, Q; Song, G; Sun, J; Yang, X, 2015)
"Fibrolamellar variant of hepatocellular carcinoma (FLHCC) does not have a favorable prognosis than conventional HCC, and there is no difference regarding the response to chemotherapy and the degree of surgical resectability."	1.40	Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. ( Akdemir, ÜÖ; Akyol, G; Boyunağa, Ö; Dalgiç, A; Demiroğullari, B; Eser, EP; Karadeniz, C; Oğuz, A; Okur, A; Pinarli, FG; Yilmaz, G, 2014)
" This study aimed to improve the bioavailability of TFU by preparing TFU-loaded lipid-based nanosuspensions (TFU-LNS) and perform a preclinical evaluation."	1.40	Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice. ( Li, M; Liu, Y; Liu, Z; Wang, L; Zhang, J; Zhang, N, 2014)
" A c-myc antisense oligodeoxynucleotide can increase the sensitivity of liver cancer cells to 5-fluorouracil and decrease the dosage of the agent necessary for efficacy, providing an experimental basis for the clinical therapy of liver cancer."	1.40	Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil. ( Cai, H; Chen, YR; Guo, TK; He, J; Li, W; Yang, XJ; Yuan, Y, 2014)
"Irinotecan (CPT-11) was used as a chemotherapeutic agent in 24 patients, gemcitabine (GEM) in 24 and doxorubicin in 59."	1.40	Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY, 2014)
"To observe the antitumor effect of Stihopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells, and study the mechanism."	1.40	[Antitumor effect of Stichopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells]. ( Chen, D; Dai, H; Song, Y, 2014)
" Changes in liver function before and after the initial TACE procedure and hepatobiliary severe adverse events (SAEs) were compared."	1.40	Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. ( Li, X; Luo, X; Tsauo, J; Wang, X; Wang, Z; Zhang, H; Zhao, H, 2014)
"For locally unresectable hepatocellular carcinoma (HCC) patients, concurrent chemoradiotherapy (CCRT) has been applied as a loco-regional treatment."	1.40	Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma. ( Choi, JS; Han, KH; Kim, JK; Kim, JW; Kim, KS; Lee, IJ; Park, YN; Seong, J, 2014)
"To study the synergistic effect on hepatoma cell(SMMC-7721) and the reduction killing effect on normal liver cells(LO-2) treated with sodium cantharidinate (SCA) in combination with fluorouracil(5-FU) or cisplatin(DDP) as well as the related mechanism."	1.40	[Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism]. ( Chen, MJ; Xu, DQ; Zhang, X; Zhao, FM; Zhao, RL; Zhou, KF, 2014)
"The prognosis of hepatocellular carcinoma (HCC) with macroscopic vascular invasion is extremely poor even after hepatic resection."	1.39	Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Nitta, H, 2013)
"The incidence of advanced hepatocellular carcinoma (HCC) is increasing worldwide, and its prognosis is extremely poor."	1.39	Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. ( Azumi, J; Gonda, K; Kanki, K; Mizuta, Y; Nagano, H; Sakabe, T; Shiota, G; Shomori, K; Tsuchiya, H; Wada, H; Yamada, D, 2013)
"The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus remains poor."	1.39	PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2013)
"The growth of H22 hepatoma transplantation tumor was inhibited more obviously in the combination group and the 5-Fu group than in the control group (P <0."	1.39	[Research on the effect and mechanism of polypeptide extract from scorpion venom combined with 5-fluorouracil on vasculogenic mimicry of H22 hepatoma]. ( Jia, Q; Wang, ZP; Wang, ZX; Wu, LC; Zhang, WD; Zhang, YY; Zheng, AH, 2013)
"Combination therapies may increase the antitumor effects and reduce the adverse effects for the treatment of hepatocellular carcinoma."	1.39	Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. ( Guo, QL; Lu, ZJ; Sha, YY; Yao, J; You, QD; Zhao, L; Zhao, Q; Zhu, BB, 2013)
"Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port."	1.39	Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Choi, JY; Chun, HJ; Kim, HY; Lee, HG; Lee, SW; Lee, YJ; Oh, JS; Song, DS; Song, MJ; Yoon, SK, 2013)
"Here, we used the chitosan and hepatoma cell-specific binding molecule, glycyrrhetinic acid (GA), to synthesize glycyrrhetinic acid-modified chitosan (GA-CTS)."	1.39	Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo. ( Chen, H; Cheng, M; Gao, X; Han, J; He, B; Li, Y; Wang, Y; Xu, H; Zhang, Z, 2013)
"The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor."	1.39	Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013)
"Advanced hepatocellular carcinoma (HCC) with portal vein invasion or intrahepatic metastases has an unfavorable prognosis, even after curative hepatic resection."	1.39	Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. ( Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuo, K; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2013)
"A 44-year-old man with advanced hepatocellular carcinoma (HCC) was admitted to our institution."	1.39	[A case of hepatocellular carcinoma (Vp4)-combination therapy prolonged survival in a patient with advanced hepatocellular carcinoma with a tumor thrombus in the portal vein trunk]. ( Kanbara, Y; Tai, K; Terai, S, 2013)
"Capecitabine was given concomitantly at a dose of 600 mg/m2 twice daily during radiotherapy."	1.39	Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Jang, JW; Kay, CS; Kim, JY; Kim, KJ; Kwon, JH; Yoo, EJ, 2013)
"The only drug that improves survival in hepatocellular carcinoma is sorafenib."	1.38	Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012)
"The prognosis for hepatocellular carcinoma (HCC) along with portal vein tumor thrombi (PVTT) is poor, and surgery has not been considered an option."	1.38	Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. ( Liu, B; Liu, J; Ou, Q; Wang, Y; Zhang, D, 2012)
"Low-dose metronomic chemotherapy involves the frequent administration of comparatively low doses of cytotoxic agents with no extended breaks, and it may be as efficient as and less toxic than the conventional maximum tolerated dose therapy."	1.38	Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. ( Bae, SH; Cha, JH; Choi, BG; Choi, JY; Chun, HJ; Jang, JW; Kim, HL; Woo, HY; Yoon, SK; Youn, JM, 2012)
"To investigate the therapeutic efficacy of lipoteichoic acid of Bifidobacterium (BLTA) in combination with 5-fluorouracil (5-FU) treatment on the mice bearing inoculated hepatoma-22 (H(22)) cells and the effects of BLTA on immunological regulation of organism, and explore its mechanisms."	1.38	Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression. ( Guo, B; Li, FR; Wang, Q; Wang, Y; Xie, N, 2012)
"5-fluorouracil (5-FU) was administered continuously for 24 h from day 1 to day 5 every 2-4 wk via an injection reservoir."	1.38	Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? ( Fujita, K; Imajo, K; Kato, S; Kirikoshi, H; Kobayashi, N; Kubota, K; Maeda, S; Mawatari, H; Nakajima, A; Saito, S; Suzuki, K; Yoneda, M, 2012)
"Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulin-like growth factor (IGF)-1 levels."	1.38	Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. ( Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY, 2012)
"Baicalein treatment significantly inhibited tumor growth of HCC xenografts in mice."	1.38	Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. ( Huang, C; Le, XF; Li, J; Li, ZF; Liang, RR; Liu, PJ; Qi, JA; Wang, ZD; Yang, J; Zhang, S, 2012)
"Thirty-six hepatocellular carcinoma patients not indicated for surgical resection underwent super- selective transcatheter arterial chemoembolization, divided into small dose (n=15) and conventional dose (n=21) chemotherapy groups."	1.38	Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. ( Hu, Y; Li, H; Li, N; Zhou, Y, 2012)
"The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy."	1.38	Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012)
"Flow cytometry and TUNEL assays in hepatic cancer cells showed that GC/5-FU was associated with higher rates of G0-G1 arrest and apoptosis than 5-FU."	1.38	5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. ( Chen, H; Cheng, M; Han, J; He, B; Li, Q; Wan, T; Wang, W; Xu, H; Yang, F; Ye, T; Zha, B; Zhu, W, 2012)
"The relevant literature regarding treatment of liver cirrhosis complicated with HCC and synchronous colon Ca reveals poor and controversial outcomes."	1.38	How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer? ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012)
"The chemoresistance of human hepatocellular carcinoma (HCC) to cytotoxic drugs, especially intrinsic or acquired multidrug resistance (MDR), still remains a major challenge in the management of HCC."	1.38	Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. ( Cheng, BB; Fang, FF; Gu, W; Li, B; Ling, CQ, 2012)
"To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer."	1.38	[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012)
"The impact of diabetes mellitus on the treatment of hepatocellular carcinoma, especially chemotherapy, is uncertain."	1.37	Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma. ( Fang, JL; Feng, YH; Huang, WT; Lin, CY; Tsao, CJ; Wu, CL, 2011)
"There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus."	1.37	Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL."	1.37	Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011)
"Arsenic trioxide was added prior to a tyrosine kinase inhibitor or to a slightly modified PIAF regimen with capecitabine replacing 5-fluorouracil."	1.37	Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011)
" A concentration- or dose-response relationship was shown between the concentration and dose of CH and Rho123 accumulation or the antitumor activity."	1.37	Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo. ( Cai-Hong, Z; Fang, M; Jin-Hua, J; Li, H; Ning, W; Qing-Duan, W; Xiao-Juan, G; Yan, Z, 2011)
"Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways."	1.36	Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B. ( Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB, 2010)
"Established human hepatocellular carcinoma adriamycin (ADM) multi-drug resistant cell sub-lines models Bel-7402/ADMV, Bel-7402/ADML and Bel-7402/ADMS by three methods of in vitro concentration gradient increased induction, nude mice liver-implanted induction and subcutaneous-implanted induction respectively."	1.36	Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods. ( Gong, R; Meng, X; Xiong, M; Zhong, X, 2010)
"5-fluorouracil was used as a positive control."	1.36	Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. ( Chaijaroenkul, W; Itharat, A; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2010)
"To observe the effects of the anti-liver cancer pharmacodynamic action of the Rougan Jiedu formula through the experiments of inhibiting cell proliferation of the tumour cell in vitro."	1.35	[The study of Rougan Jiedu formula anti-liver cancer in vivtro]. ( Li, H; Wu, CJ, 2008)
"Prognosis of advanced hepatocellular carcinoma is dismal when locoregional treatments have failed."	1.35	Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. ( Codecà, C; Di Maria, G; Fazio, N; Ferrari, D; Fiore, J; Foa, P; Luciani, A; Maggioni, M; Oldani, S, 2008)
"d-Allose is a novel anti-tumor monosaccharide that causes cell growth inhibition, specifically of the cancer cells, by inducing the tumor suppressor gene thioredoxin interacting protein (TXNIP)."	1.35	Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7. ( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008)
"Tree 1-7 on human hepatoma cell line HepG2 cultured in vitro."	1.35	[Cytotoxicity of the secondary metabolites of Marine Mangrove Fungus Paecilomyces sp. tree 1-7 on human hepatoma cell line HepG2]. ( Cai, XL; Gao, JP; Li, Q; Lin, YC; She, ZG; Wen, L, 2008)
" The life prolongation rate, toxic reactions of chemotherapy, WBC count, the body weight, tumor weight, thymus index and spleen index, and phagocytic function of intra-abdominal macrophages were investigated in the H22 tumor-bearing mice."	1.35	The effect-enhancing and toxicity-reducing action of the extract of herba Scutellariae barbatae for chemotherapy in hepatoma H22 tumor-bearing mice. ( Dai, Z; Diao, Y; Ji, Z; Kang, H; Liu, L; Liu, X; Wang, X, 2008)
"There were upper gastrointestinal hemorrhage in 3 cases, hepatic failure in 4, pulmonary embolism in 1, cholecystitis in 4, hepatic encephalopathy in 2, gastric perforation in 1, and intrahepatic biloma in 2 cases."	1.35	[Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma]. ( Feng, B; Liang, SN; Liu, LL; Su, HY; Xu, K; Zhao, GS, 2008)
" Transcatheter arterial chemoembolization is a standard treatment option for patients with unresectable HCC, especially when combined with other therapies."	1.35	A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization. ( Liu, J; Sui, J; Tian, G, 2009)
"Hepatocellular carcinoma was the second most frequent malignancy to be observed--23 patients (18."	1.35	[Advanced hepatic resection for malignancy]. ( Kotel'nikov, AG; Patiutko, IuI; Pylev, AL; Sagaĭdak, IV, 2009)
"To determine the influence of HBx gene RNA interference combined with chemotherapy on stable hepatocellular carcinoma cells growth and its apoptosis mechanism."	1.35	[Effect of HBx gene RNA interference combined with chemotherapy on hepatocellular carcinoma cells]. ( He, X; He, Y; Lei, J; Sun, H; Wang, W, 2009)
": Patients with unresectable hepatocellular carcinoma (HCC) have limited treatment options."	1.35	Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. ( Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G, 2009)
"To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE)."	1.35	[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer]. ( Chen, LH; Guan, J; Li, QS; Sun, HW; Wei, CJ; Zheng, XK, 2009)
"A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT."	1.35	[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. ( Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K, 2009)
"However, the immunological features of liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by intra-arterial chemotherapy are still unclear."	1.35	Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. ( Higami, K; Ikehara, T; Kanayama, M; Matsui, T; Miki, K; Miyaki, D; Momiyama, K; Nagai, H; Sumino, Y; Watanabe, M, 2008)
"We developed a recombinant defective adenovirus with an insert of gene encoding extracellular domain of mouse Flt3L (Ad-mFlt3L) under control of cytomegalovirus promoter to investigate the biological efficacy of Flt3L in combination with chemotherapeutical drug, 5-FU, in eliciting an effective anti-cancer immunity in mouse hepatoma and colon cancer model systems."	1.34	Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU. ( Dai, J; Fan, X; Guo, Y; Hou, S; Kou, G; Li, B; Li, J; Lin, B; Ma, J; Qian, W; Wang, H; Wu, M; Zhang, D; Zhao, J, 2007)
"Two different hepatoma cell lines were incubated for 48h with chemotherapeutic drugs cisplatin, paclitaxel and 5-FU to determine their ability to induce cytotoxicity and DNA fragmentation as well as to modify the expression of some cell death-related genes that could be involved in the resistance to therapy."	1.34	Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance. ( Arce, F; Brenes, O; Díaz, C; Gätjens-Boniche, O, 2007)
" In this study, we evaluated the response to hepatic arterial infusion of 5-fluorouracil (5-FU) in combination with subcutaneous interferon (IFN)-alpha in patients with advanced HCC."	1.34	Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. ( Adachi, Y; Araki, J; Furjita, N; Horiike, S; Itani, T; Iwasa, M; Kaito, M; Kobayashi, Y; Konishi, M; Kuroda, M; Mifuji, R; Tanaka, H; Urawa, N; Yamamoto, M, 2007)
"Cell proliferation assay in human hepatoma cells (HepG 2) was performed using 5-FU and/or various IFNs-alpha (C-IFN, Intron A, OIF)."	1.34	[Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells]. ( Fan, XY; Iwaki, K; Kai, S; Kitano, S; Ohta, M; Shibata, K; Uchida, H, 2007)
"A non-invasive orthotopic hepatocellular carcinoma (HCC) model was created with human HCC cells (HepG-Luc) constitutively expressing luciferase (Luc) in nude mice."	1.34	Bioluminescent imaging of hepatocellular carcinoma in live mice. ( Peng, J; Sun, Z; Wang, Y; Zhan, L, 2007)
"Case 1 was a 71-year-old woman with a hepatocellular carcinoma (HCC), 45 mm in diameter, with liver cirrhosis."	1.34	[Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy]. ( Hirashita, T; Nakashima, K; Sakai, I; Sakai, M, 2007)
"5-fluorouracil (5-FU) is a basic agent used in chemotherapy."	1.34	Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue. ( Ebara, M; Nomura, F; Saisho, H; Shimada, H; Sunaga, M; Tomonaga, T; Yoshikawa, M, 2007)
"Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2."	1.34	Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007)
"The prognosis of patients with advanced hepatocellular carcinoma (HCC) is poor."	1.33	Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. ( Aoyama, K; Ishikawa, T; Kawaguchi, K; Kimura, T; Kurokawa, F; Okita, K; Omori, K; Sakaida, I; Tajima, K; Takami, T; Terai, S; Tsuchiya, M; Yamasaki, T; Yokoyama, Y, 2005)
"Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor."	1.33	[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C]. ( Ahn, SH; Cho, KB; Choi, JS; Chung, WJ; Hwang, JS; Hwang, JY; Jang, BK; Kim, GC; Kim, YH; Kwon, JH; Kwon, KM; Park, KS, 2005)
"A 72-year-old man who had multiple hepatocellular carcinoma underwent eight times intrahepatic arterial chemotherapies of SMANCS and two times percutaneous ethanol injection (PEIT) therapies over three years, but new diffuse lesions appeared in the liver."	1.33	[A case of hepatocellular carcinoma with multiple lung metastases responding to intermittent intrahepatic arterial chemotherapy of CDDP+5-FU]. ( Arima, T; Horino, K; Inoue, M; Kimura, M; Kuhara, H; Nishimura, T; Uemura, K; Yamada, K, 2005)
"Treatment for advanced stages of hepatocellular carcinoma (HCC) remains unsatisfactory."	1.33	The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. ( Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S, 2005)
"An in situ human hepatocellular carcinoma model was established in mice livers orthotopically."	1.33	Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. ( Lin, RX; Lü, QJ; Tuo, CW; Wang, SQ; Zhang, W, 2005)
"Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation."	1.33	5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005)
"The prognosis of hepatocellular carcinoma (HCC) with tumor thrombosis of the main trunk or major branches of the portal vein (mPVTT) is extremely poor, even if it is curatively resected."	1.33	Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. ( Mimura, T; Niguma, T; Tutui, N, 2005)
"While 5-Fu causes mainly apoptosis in hepatoma cells, the anticancer mechanism of paclitaxel is predominantly through induction of necrosis."	1.33	[Effects of paclitaxel and 5-fluorouracil on growth inhibition and apoptosis of hepatoma cells: a comparative study]. ( He, JB; Ji, MF; Li, XL; Yu, YL, 2005)
"Hepatocellular carcinoma (HCC) and pancreatic cancer are at the forefront of chemotherapy-resistant tumors with poor prognosis."	1.33	5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. ( Imazeki, F; Kanda, T; Nagao, K; Saisho, H; Tada, M; Yokosuka, O, 2005)
"Diffused hepatoma was involved in the posterior lobe, and tumor thrombus extended into the main portal vein (Vp4)."	1.33	[A case report of hepatocellular carcinoma (Vp4)--an attempt to reduce residual tumor thrombus using combination therapy (hepatic arterial infusion, hepatic arterial embolization and radiation)]. ( Ebisui, C; Fujimoto, T; Fujiwara, S; Fukuchi, N; Hasuike, Y; Hayashi, N; Izumiyama, K; Kida, H; Koshino, T; Sakita, I; Tsujie, M; Yoshida, T, 2005)
"For 15 patients with advanced hepatocellular carcinoma using a same protocol, the response rate of this therapy was 33."	1.33	[Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports]. ( Bazarragchaa, D; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Murakami, T; Nagano, H; Nakamura, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H; Yoshioka, S, 2005)
"Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis."	1.33	[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006)
" 3DCRT was given with the field covering the tumor with a generous margin."	1.33	[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma]. ( Chen, Z; Cheng, WW; Jiang, GL; Lin, JH; Liu, LM; Meng, ZQ; Zhang, XJ; Zhou, ZH, 2006)
"The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal."	1.33	[A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006)
"Recently, we reported the beneficial effects of intra arterial 5-FU infusion chemotherapy combined with interferon-alpha (IFN-alpha/5-FU combined chemotherapy) for advanced hepatocellular carcinoma (HCC)."	1.33	[Intra arterial infusion chemotherapy combined with interferon-alpha following palliative hepatic resection against advanced hepatoma with portal venous tumor thrombus in the major trunk and multiple nodules--a preliminary study]. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H, 2006)
"We report a case of advanced hepatocellular carcinoma (HCC)."	1.33	[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL]. ( Amano, M; Fujita, M; Hayashida, H; Higaki, N; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M; Yamashita, S, 2006)
"A syngeneic rat model of hepatocellular carcinoma was used."	1.32	[Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats]. ( Jiang, GP; Li, MW; Xie, HY; Yang, FC; Zeng, QL; Zheng, SS, 2003)
"The prognosis of advanced hepatocellular carcinoma remains poor."	1.32	Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. ( Ando, E; Fukumori, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y, 2003)
"Human hepatoma HepG2 cells were treated with 5-Fu at the concentrations of 1X10(-1), 1X10(-2), 1X10(-3), 1X10(-4), 1X10(-5) mol/L and for 1, 2, 4, 8, 16, 24 hours, respectively."	1.32	Caspase-8 in apoptosis of hepatoma cell induced by 5-fluorouracil. ( Yang, LY; Yi, TB, 2003)
"Nineteen patients with far advanced hepatocellular carcinoma received transarterial hepatic chemotherapy."	1.32	[Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy]. ( Furukawa, H; Imamura, H; Inoue, Y; Ishida, H; Kitamura, S; Masuda, F; Masutani, S; Obana, T; Ohnishi, H; Saeki, N; Shimizu, J; Takamura, M; Tatsuta, M; Tomotsu, K; Yura, M, 2003)
"The prognosis of advanced hepatocellular carcinoma (HCC) is extremely poor."	1.32	[A report of two cases--two patients of the extremely advanced hepatocellular carcinoma have responded completely for a long time after a combination therapy consisting of arterial chemotherapy and injection of interferon-alpha]. ( Danno, M; Dono, K; Hatanaka, T; Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Monden, M; Nagano, H; Nakamori, S; Naoi, Y; Ohshima, S; Sakon, M; Tsujie, M; Umeshita, K; Yamamoto, H, 2003)
"Five human hepatoma cell lines (Hep3B, HepG2, HuH7, PLC/PRF/5 and Chang) were used."	1.32	The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. ( Iwasaki, T; Kogure, T; Shimosegawa, T; Ueno, Y, 2004)
"5-fluorouracil (5-FU) that has no carbonyl group was used as control."	1.32	[Screening of the drug resistance-associated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1)]. ( Cao, DL; Tang, DN; Wang, J; Yang, XD, 2003)
"To study the anti-tumor effect of resveratrol and in combination with 5-FU on murine liver cancer."	1.32	Effect of resveratrol and in combination with 5-FU on murine liver cancer. ( Meng, KW; Pan, CE; Qin, XL; Sun, ZJ; Wu, SL; Yu, L, 2004)
"The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein."	1.32	Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. ( Dono, K; Ishii, S; Kato, K; Kurokawa, Y; Matoba, R; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takemasa, I; Ueno, N; Umeshita, K, 2004)
"To explore the change of T cell subsets in patients suffered from hepatocellular carcinoma (HCC) before and after hepatectomy, and study the value of Roferon-A (interferon alpha-2a) combined with hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) after radical resection of HCC for preventing recurrence."	1.32	[The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence]. ( Chen, JS; Duan, ZH; Li, HH; Wang, J; Zhang, HW, 2004)
" The sensitivity of H22 cells to 5-FU can be markedly enhanced: The IC(50) dosage of 5-Fu can be decreased from 0."	1.31	The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo. ( Li, Z; Liu, J; Qi, S; Wang, T; Zhang, J; Zhu, H, 2002)
"Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC)."	1.31	[Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC]. ( Ito, T; Kamachi, H; Kamiyama, T; Kondo, M; Kurauchi, N; Matsushita, M; Nakagawa, T; Nishikawa, M; Ogata, T; Todo, S, 2002)
"The prognosis of patients with advanced hepatoma is grim."	1.31	Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells. ( Goto, T; Hoshida, Y; Kato, N; Moriyama, M; Omata, M; Otsuka, M; Seki, N; Shiratori, Y; Taniguchi, H, 2002)
"A case of hepatocellular carcinoma (HCC) complicated by tumor thrombosis of the main trunk is presented."	1.31	Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus. ( Ando, E; Fukumori, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y, 2000)
"Capecitabine may inhibit the growth and metastasis of HCC."	1.31	[The expression of platelet-derived endothelial cell growth factor in liver cancer]. ( Fan, J; Tang, Z; Zhou, J, 2000)
"We reported a case of hepatocellular carcinoma (HCC) with multiple lymph node metastases."	1.31	[Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases]. ( Beppu, T; Fujiyama, S; Hirota, M; Ishiko, T; Ishiodori, H; Matsuda, T; Ogawa, M; Omuraya, M; Yamashita, Y, 2001)
"Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis, and the development of new therapeutic strategies is necessary."	1.31	Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. ( Kaneko, S; Kobayashi, K; Urabe, T, 2002)
"If hepatic reserve is satisfactory, an aggressive surgical approach combined with chemotherapy seems to be of benefit for patients having HCC with tumor thrombus in the MPV, IVC, or EBD."	1.31	Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. ( Aoyagi, S; Eriguchi, N; Fukuda, S; Imamura, I; Imamura, M; Okuda, K, 2002)
"The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor."	1.31	Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002)
"For 6 patients with advanced hepatocellular carcinoma (HCC) in whom TAE was inefficacious, we tried hepatic arterial infusion chemotherapy."	1.30	[Hepatic arterial infusion chemotherapy (HAI) for advanced hepatocellular carcinoma inefficacious with transcatheter arterial embolization (TAE)]. ( Aoyama, H; Asano, T; Fukunaga, T; Isono, K; Iwasaki, K; Kenmochi, T; Kobayashi, S; Kouno, T; Matsuzaki, H; Nakagouri, S; Okazumi, S; Shinotou, K; Shutou, K; Takayama, W; Takeda, A, 1998)
"Five different human hepatoma cell lines, Hep G2, Hep G2."	1.30	Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. ( Jiang, S; Kim, SJ; Lee, MO; Park, JH; Shin, EC; Song, MJ, 1999)
"The innate drug resistance of human hepatocellular carcinoma (HCC) Bel7402 cell line was studied in vitro."	1.30	The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. ( Huang, M; Liu, G, 1999)
"AFP gene expression in human hepatoma cells was determined by avidin-biotin-peroxidase complex (ABC) immunocytochemical method."	1.30	Combined effect of alpha-fetoprotein antisense oligodeoxy-nucleotides and 5-fluorouracil on human hepatoma cell growth. ( Wang, X; Xie, H; Zhang, R, 1999)
"Primary hepatocellular carcinoma is a very rare disease, especially in association with a pregnancy."	1.29	[Hepatocellular carcinoma in pregnancy]. ( Brucker, C; Debus-Thiede, G; Genz, T; Maassen, V; Schweiberer, L; Weiss, M, 1994)
"A-68-year-old man had hepatocellular carcinoma (HCC) in the area of S6 segment which was resected surgically."	1.29	[A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer]. ( Fukuzawa, Y; Ikeda, H; Kato, K; Murata, K; Sawada, T; Tagaya, T; Takahashi, K; Takiya, S, 1996)
"In seven patients with advanced primary hepatocellular carcinoma the same therapeutic regime was used."	1.28	Hepatic chemoinfusion of 5-FU in metastasis of gastrointestinal cancer and advanced primary hepatocellular carcinoma. ( Cuan-Orozco, F; Kalk, JF; Koussouris, P; Mercado, MA; Paquet, KJ; Siemens, F, 1992)
" After right lobectomy of the liver which contained the tumors of S6 2 cm and S8 3 cm in diameter 7 months before, the patient was treated with hepatic arterial embolization (TAE) combined with infusion of anti-cancer drug (ADM, CDDP) four times since June 1990."	1.28	[A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE]. ( Imai, Y; Ito, J; Kobayashi, K; Okamoto, M; Tagawa, K; Taniguchi, M; Tanzawa, Y; Toda, N; Unuma, T; Uta, Y, 1992)
"Hepatectomy has been performed as a treatment for hepatocellular carcinoma (HCC) and metastatic liver carcinoma."	1.28	[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma]. ( Hanawa, S; Hasebe, Y; Kuramoto, S; Maeda, T; Nakazaki, H; Suzuki, Y; Watanabe, M; Yanagita, K; Yoshio, T, 1992)
"Four cases of advanced hepatocellular carcinoma patients were treated by intra-portal infusion of 5-FU immediately after surgery."	1.28	[Intraportal vein infusion chemotherapy after hepatectomy for hepatocellular carcinoma--preliminary report]. ( Gotoda, A; Kamiyama, T; Nagabuchi, E; Nakajima, Y; Ogasawara, K; Saito, M; Sato, N; Uchino, J; Une, Y, 1991)
"Chemosensitivity of hepatocellular carcinoma tissues from 72 patients to 6 antitumor agents was assayed using the succinate dehydrogenase inhibition test."	1.28	Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test. ( Akazawa, K; Kanematsu, T; Maehara, Y; Matsumata, T; Shirabe, K; Sugimachi, K, 1991)
"Fifteen patients with advanced hepatocellular carcinoma were treated by hepatic arterial infusion (HAI)."	1.28	[Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU]. ( Akimura, R; Fujii, N; Ikami, I; Kanehira, J; Kimura, T; Midorikawa, H; Nakamura, Y; Sasaki, T; Tarusawa, K; Yodono, H, 1990)
" Thus, both intraarterial and intraportal chemotherapy combined with decollateralization by silicone rubber sheeting seems to be effective for advanced cholangiocarcinoma and metastatic carcinoma."	1.28	[Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer]. ( Fukuda, I; Furukawa, H; Imaoka, S; Ishikawa, O; Masutani, S; Nagano, H; Ohashi, I; Oohigashi, H; Sasaki, Y; Yasuda, T, 1990)
"Two patients had primary hepatocellular cancer (HCC)."	1.28	Repeated dearterialization of hepatic tumors with an implantable occluder. ( Bengmark, S; Ekberg, H; Jeppsson, B; Lundstedt, C; Persson, BG; Tranberg, KG, 1990)
"Human hepatoma and melanoma tumor cells and normal melanocytes, keratinocytes, and fibroblasts were incubated for 2, 24, and 48 h with graded concentrations of cis-platinum (0."	1.28	Rapid chemosensitivity assay with human normal and tumor cells in vitro. ( Babich, H; Borenfreund, E; Martin-Alguacil, N, 1990)
"Six cases of unresectable hepatic cancer in infant were treated with intra-arterial infusion therapy."	1.28	[Clinical study of intrahepatic arterial infusion of unresectable hepatoblastoma and hepatocarcinoma in children]. ( Abe, T; Hamada, H; Hata, Y; Saito, H; Sasaki, F; Sato, N; Sawada, H; Tamura, M; Uchino, J; Une, Y, 1989)
"In the case of gall bladder cancer cell line (NOZ), combination of adriamycin and hyperthermia showed more effective inhibition for cell proliferation than MMC + hyperthermia and 5-FU + hyperthermia."	1.28	[Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro]. ( Fujise, K; Hasumura, S; Homma, S; Kameda, H; Matsuura, T; Nagamori, S; Niiya, M; Shimizu, K; Sujino, H, 1989)
"Lipiodol-ADM was injected for hepatocellular carcinoma every 2 months and MMC-5-FU was injected for liver metastasis of colorectal carcinoma every one or two weeks."	1.28	[Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma]. ( Adachi, W; Hanasaki, K; Horigome, N; Iida, F; Kajikawa, S; Kinosita, T; Kuroda, T; Sodeyama, H, 1989)
"In 24 cases of unresectable hepatocellular carcinoma, we performed hepatic arterial catheterization and intra-arterial infusion chemotherapy."	1.28	[Hepatic arterial infusion chemotherapy of hepatocellular carcinoma]. ( Amioka, K; Hara, H; Iga, C; Ishibashi, T; Isozaki, H; Morita, S; Nakata, E; Nishimura, J; Okajima, K; Tanimura, M, 1989)
"Of the 8 patients having hepatoma with increased AFP, all the patients showed a decrease of AFP following the therapy with an average ratio of 65% decrease."	1.28	[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]. ( Haida, K; Miura, T, 1989)
"Nineteen patients with primary hepatocellular carcinoma (7 were at Stage III and 11 were at Stage IV) and 14 patients with metastatic liver tumors (4 were at H2 and 9 were at H3 stages) received this newly developed anticancer methodology."	1.28	[The clinical studies of intermittent hepatic artery occlusion with infusion chemotherapy--19 cases of unresectable hepatocellular carcinoma and 14 cases of metastatic liver cancer]. ( Naito, A; Nakase, A; Tamura, K; Tarumi, T; Yamamoto, T; Yano, S, 1989)
"A 24-year-old man with hepatocellular carcinoma presented with recurrent obstructive jaundice caused by bile duct invasion and distal migration of necrotic tumor fragments."	1.27	Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma. ( Albaugh, JS; Keeffe, EB; Krippaehne, WW, 1984)
"Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin."	1.27	[Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma]. ( Hino, I; Kimura, I; Kuroda, S; Numoto, A; Ohnoshi, T; Takahashi, M; Tsuji, M; Ueoka, H, 1984)
"Although both patients with hepatocellular cancer and the patient with a soft tissue sarcoma responded to the regimen, only 1 of 38 patients with adenocarcinoma had a favourable response."	1.27	Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer. ( Cedermark, BJ; Gunven, P; Hammarberg, C, 1983)
"A 9-year-old boy with non-resectable hepatocellular carcinoma was treated with irradiation and intra-hepatic arterial infusion of antitumor agents."	1.27	[HBs antigen-positive adult type liver cancer in a child with sustained remission induced by infusion of antineoplastic agents into the hepatic artery]. ( Hamawaki, M; Ito, Y; Iwata, K; Kikkawa, K; Kubonishi, S; Kuroiwa, Y; Matsuoka, K; Ohmura, T; Okano, K, 1983)
"Fourty eight patients with cancer of head of pancreas have been treated by the intra-arterial infusion of 5-FU and Mitomycin C alone or in combination with regional hyperthermia, employing microwave machine operating at a frequency of 2450 MHz."	1.27	[Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas]. ( Endo, Y; Funatomi, H; Hatta, Y; Hirose, N; Miura, T; Sassa, T; Taguchi, S; Yoshikawa, N, 1985)
"Thirty-two patients with inoperable hepatic cancer underwent intra-arterial hepatic infusion using mitomycin C (MMC) and 5-fluorouracil (5-FU) or intra-arterial hepatic chemoembolization using heated albumin microspheres containing MMC with an average diameter 45 +/- 8 micron."	1.27	Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil. ( Endoh, F; Fujimoto, S; Miyazaki, M; Morimoto, Y; Okui, K; Takahashi, O, 1985)
"Twenty patients with malignant hepatoma were treated with sequential intraarterial doxorubicin (72-hour continuous infusion) followed by systemic 5-fluorouracil (5-FU) and semustine (methyl CCNU)."	1.27	Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine. ( Hahn, RG; Moertel, CG; O'Connell, MJ; Rubin, J, 1988)
"5-fluorouracil was effective only in patients without cirrhosis, with an overall response rate of 22%."	1.27	Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. ( Audisio, R; Bignami, P; Bonfanti, G; Bozzetti, F; Colombo, M; Doci, R; Gennari, L, 1988)
"Of the 8 patients with hepatoma with increased AFP, all the patients showed a decrease of AFP following therapy with an average decrease ratio of 64%."	1.27	[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]. ( Haida, K; Miura, T, 1988)
"A total of 850 patients with hepatocellular carcinoma seen during the last 8 years were analyzed retrospectively for survival in relation to treatment and disease stage."	1.27	Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. ( Hasegawa, H; Nakajima, Y; Obata, H; Ohnishi, K; Ohtsuki, T; Okazaki, N; Okuda, K; Tomimatsu, M, 1985)
"All of the gallbladders had significant arteritis, with narrowing or occlusion of lumina or necrosis of vessel walls."	1.27	Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump. ( Dakhil, SR; Housholder, DF; Marymont, JV; Travers, H, 1985)
"407 cases of unresectable hepatocellular carcinoma (HCC) occurring from 1970 to March 1985, including 107 cases receiving conservative therapy, 176 cases receiving one-shot therapy and 124 cases receiving transcatheter arterial embolization (TAE) therapy, were studied and the efficacy of chemotherapy was compared with that of TAE therapy."	1.27	[One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kawazoe, Y; Kumagai, M; Tanikawa, K; Yamashita, K, 1985)
"Four hepatocellular cancer patients and 11 metastatic liver cancer patients were treated with intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) plus 5-fluorouracil."	1.27	Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors. ( Koga, S; Maeta, M; Murakami, A; Wakatsuki, T; Yoshioka, H, 1985)
"5-Fluorouracil was injected by a fine needle under ultrasound guidance."	1.27	Percutaneous interstitial chemotherapy of a small hepatocellular carcinoma under ultrasound guidance. ( Livraghi, T; Ravetto, C; Solbiati, L; Suter, F, 1986)
"A 69-year-old man with a large hepatoma of the right lobe extending in part to the medial segment of the left lobe was treated by ligation of the right hepatic artery combined with continuous infusion of a total dose of 5500 mg og 5-fluorouracil (5-FU) into the left hepatic artery."	1.26	A non-resectable hepatoma after hepatic artery ligation combined with infusion chemotherapy--an eight-year survival. ( Hiraoka, T; Konno, T; Nakakuma, K; Tashiro, S; Yokoyama, I, 1981)
"5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma."	1.26	Metabolic and distribution studies with radiolabeled 5-fluorouracil. ( Ghanbarpour, A; Shani, J; Siemsen, JK; Vine, E; Wolf, W; Young, D, 1982)
"One patient with hepatocellular carcinoma had compete disappearance of all disease with chemotherapy alone."	1.26	Preoperative chemotherapy for unresectable primary hepatic malignancies in children. ( Siegel, MM; Siegel, SE; Stanley, P; Weinblatt, ME; Weitzman, JJ, 1982)
"N1-S1/FdUrd Novikoff hepatoma cells, which lack thymidine kinase activity, are resistant to 5-fluorouracil (FUra) as well as 5-fluorodeoxyuridine (FdUrd), suggesting that the pathway, FUra leads to FdUrd leads to FdUMP, is utilized for the conversion of FUra to FdUMP."	1.26	Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. ( Crumley, J; Wilkinson, DS, 1977)
" Maintenance therapy was carried out by the administration of these drugs at induction dosage alternated each week as a single 24 hourly intravenous infusion."	1.26	Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. ( Das, B; Jaiswal, MS; Misra, NC; Singh, RV, 1977)
"Oral fluorouracil was administered weekly to 12 consecutive patients with unresectable hepatoma."	1.26	Oral fluorouracil therapy of hepatoma. ( Kennedy, PS; Lane, M; Lehane, DE; Smith, FE, 1977)
"The podophyllotoxin derivative VP 16-213 was used as monotherapy in 6 patients and combined with 5-fluorouracil in another 6."	1.26	[Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)]. ( Brunner, KW; Cavalli, F; Gerber, A; Ryssel, HJ; Sonntag, RW; Tschopp, L, 1977)
" Comparison of the effects of single vs fractionated dosage was made on 2 types of experimental solid tumour with different growth, cell kinetic, histological and metastasizing properties."	1.26	Solid tumour models for the assessment of different treatment modalities: VII: single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts. ( Hopkins, HA; Looney, WB; Macleod, MS, 1978)
"A case of hepatocellular carcinoma in a young female is presented in which the apparent etiology was the use of oral contraceptives for 5 1/2 years."	1.26	Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives. ( Gattanell, PN; Holland, JF; Perloff, M, 1978)
"A 45-year-old man with hepatocellular carcinoma who developed intravascular coagulation following complete tumor regression by chemotherapy is described."	1.26	Complete necrotization of hepatocellular carcinoma by chemotherapy and subsequent intravascular coagulation: a case report. ( Harada, T; Makisaka, Y; Nishimura, H; Okuda, K, 1978)
"A case of hepatocellular carcinoma associated with erythrocytosis is described."	1.26	Hepatocellular carcinoma associated with erythrocytosis. A nine year survival after successful chemotherapy and left lateral hepatectomy. ( Arima, M; Hattori, N; Kimura, K; Okazaki, N; Ozaki, H, 1979)
"Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma."	1.26	Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979)
"Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts."	1.25	Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975)

Timeframe	Studies, this research(%)	All Research%
pre-1990	211 (19.38)	18.7374
1990's	115 (10.56)	18.2507
2000's	294 (27.00)	29.6817
2010's	369 (33.88)	24.3611
2020's	100 (9.18)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Trial of Hepatic Arterial inFusion Chemotherapy Sequential transaRterial Embolization cOmbined With leNvatinib and Tislelizumab in Unresectable Hepatocellular Carcinoma (FRONT Trial)[NCT05532319]	Phase 2	65 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma[NCT05609695]		100 participants (Anticipated)	Observational	2023-03-01	Not yet recruiting
A Study of the Application of Hepatic Arterial Infusion in Advanced Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors and Antiangiogenic Agents[NCT05718492]		100 participants (Anticipated)	Interventional	2022-10-18	Recruiting
Observation Study of Sequential Regorafenib Combined With Immunocheckpoint Inhibitors After Hepatic Artery Infusion Chemotherapy for Advanced Hepatocellular Carcinoma[NCT05573282]		50 participants (Anticipated)	Observational	2022-10-16	Recruiting
A Phase III Randomized Trial of Comparison of Survival Benefit of Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin With Sorafenib for Patients With Barcelona-Clinic Liver Cancer (BCLC)-C Stage Hepatocellular Carcinoma[NCT03164382]	Phase 3	262 participants (Actual)	Interventional	2017-03-01	Completed
A Randomized Controlled Study of the Efficacy of Hepatic Arterial Perfusion Chemotherapy Concurrently Compared to Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable Intermediate and Advanced HCC[NCT06041477]	Phase 3	540 participants (Anticipated)	Interventional	2023-09-30	Recruiting
Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After Hepatic Artery Infusion Chemotherapy (HAIC) for Locally Advanced Hepatocellular Carcinoma (HCC)[NCT05002452]		150 participants (Anticipated)	Observational	2021-12-20	Recruiting
An Open Label Pilot Study to Evaluate Efficacy and Safety of Durvalumab(MEDI 4736) With Hepatic Artery Infusion Chemotherapy (HAIC) in the Chinese Advanced HCC Patients With Severe Portal Vein Tumor Thrombosis (PVTT)(Vp3 or Vp4) DurHope[NCT04945720]	Phase 2	30 participants (Anticipated)	Interventional	2022-04-11	Recruiting
A Prospective, Multicenter, Phase III Clinical Study Comparing Continuous Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma[NCT05231382]	Phase 3	426 participants (Anticipated)	Interventional	2022-03-28	Recruiting
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitor in Treating Potentially Resectable Locally Advanced Hepatocellular Carcinoma: A Prospective, Phase II Clinical Study[NCT03869034]	Phase 2	40 participants (Actual)	Interventional	2019-03-25	Active, not recruiting
Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587]	Early Phase 1	60 participants (Anticipated)	Interventional	2021-07-01	Enrolling by invitation
A Randomized Controlled, Open-label, Multicenter Phase III Clinical Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib and Camreli[NCT05313282]	Phase 3	140 participants (Anticipated)	Interventional	2022-06-15	Recruiting
A Prospective, Single-arm, Phase II Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib-Mesylate Tablets and Camrelizumab for Injec[NCT04191889]	Phase 2	47 participants (Anticipated)	Interventional	2020-04-13	Recruiting
An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949]	Phase 1/Phase 2	39 participants (Anticipated)	Interventional	2019-12-01	Not yet recruiting
Neoadjuvant Radiotherapy for Patients With Hepatocellular Carcinoma Involving Type I Portal Vein Tumor Thrombus[NCT04025437]	Phase 2/Phase 3	214 participants (Anticipated)	Interventional	2019-03-01	Active, not recruiting
Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial[NCT02774187]	Phase 3	247 participants (Actual)	Interventional	2016-05-31	Completed
A Prospective, Single-armed, Multicentric, Explorative Phase II Clinical Research of Conversional Therapy With Combination of Hepatic Arterial Infusion Chemotherapy and Donafenib and Toripalimab for Unresectable Hepatocellular Carcinoma[NCT05493332]	Phase 2	93 participants (Anticipated)	Interventional	2022-09-30	Not yet recruiting
Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial[NCT02767375]	Phase 2/Phase 3	192 participants (Anticipated)	Interventional	2015-02-28	Recruiting
The Clinical Randomized Trial of Adjuvant Chemotherapy With FOLFOX in HCC Patients at High Risk After Resection[NCT02738697]	Phase 3	290 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02585479]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2015-10-31	Withdrawn (stopped due to It doesn't meet the requirements of randomized trials)
A Randomized Controlled Trial of Radical Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma[NCT02584556]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2015-10-31	Withdrawn
Gemcitabine Plus Oxaliplatin (GEMOX) Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02534337]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2015-09-30	Withdrawn (stopped due to It doesn't meet the requirements of randomized trials)
Liposomal Doxorubicin(LD) Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02527772]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2015-09-30	Withdrawn (stopped due to It doesn't meet the requirements of randomized trials)
Hepatic Resection Combined With or Without Oxaliplatin+5-Fluorouracil/ Leucovorin(5-FU/LV)(FOLFOX4) for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT02452853]	Phase 2	51 participants (Anticipated)	Interventional	2015-05-31	Active, not recruiting
RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC:an Open Lable, Single-arm, Prospective Study[NCT02426450]	Phase 2	28 participants (Anticipated)	Interventional	2015-04-30	Active, not recruiting
Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment[NCT00471965]	Phase 3	371 participants (Actual)	Interventional	2007-03-31	Completed
A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative.[NCT00970216]		160 participants (Actual)	Observational	2009-02-28	Completed
A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737]	Phase 2	125 participants (Anticipated)	Interventional	2020-01-10	Recruiting
Phase II Study of Sorafenib (Bay 43-9006) and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma.[NCT00619541]	Phase 2	46 participants (Anticipated)	Interventional	2007-01-31	Completed
A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors[NCT02404480]	Phase 1	31 participants (Actual)	Interventional	2016-01-31	Completed
Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957]		180 participants (Actual)	Observational	2006-02-28	Completed
Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427]	Phase 2	101 participants (Actual)	Interventional	2017-05-15	Completed
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]	Phase 2	200 participants (Actual)	Interventional	2015-10-05	Active, not recruiting
A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006[NCT00701168]		0 participants	Expanded Access		No longer available
Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience[NCT02557750]		35 participants (Anticipated)	Observational	2016-01-31	Recruiting
Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma[NCT02981498]	Phase 2	35 participants (Anticipated)	Interventional	2015-06-30	Completed
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma[NCT02733809]	Phase 4	40 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis[NCT01357486]	Phase 2	160 participants (Actual)	Interventional	2011-11-14	Completed
Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143]	Phase 2	30 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
The Efficacy, Safety, and Patient Reported Outcomes of Different Regimens of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma[NCT00493402]	Phase 3	365 participants (Actual)	Interventional	2007-07-31	Completed
A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy[NCT01097083]	Phase 2	20 participants	Interventional	2010-04-30	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Use of chemotherapy to treat hepatocellular carcinoma. Bioscience trends, 2022, Mar-11, Volume: 16, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap	2022
Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy. Nature protocols, 2022, Volume: 17, Issue:8 Topics: Animals; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Lipids	2022
Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: A systematic review network meta-analysis of randomized clinical trials. Cancer medicine, 2023, Volume: 12, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C	2023
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. Clinical and molecular hepatology, 2023, Volume: 29, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;	2023
Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Current opinion in pharmacology, 2023, Volume: 70 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liv	2023
Cisplatin in Liver Cancer Therapy. International journal of molecular sciences, 2023, Jun-29, Volume: 24, Issue:13 Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Fluorouracil; Humans; Liver Ne	2023
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma. Frontiers in immunology, 2023, Volume: 14 Topics: Carcinoma, Hepatocellular; Cell Death; Cisplatin; Fluorouracil; Humans; Immunotherapy; Liver Neoplas	2023
Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. Future oncology (London, England), 2014, Volume: 10, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Embolization, Ther	2014
[A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorour	2014
Progress in systemic therapy of advanced hepatocellular carcinoma. World journal of gastroenterology, 2016, Aug-07, Volume: 22, Issue:29 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Fluorourac	2016
A case of unresectable combined hepatocellular cholangiocarcinoma showing favorable response to LFP therapy. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2016, Volume: 113, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol	2016
Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget, 2017, Mar-21, Volume: 8, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ch	2017
Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent patents on anti-cancer drug discovery, 2008, Volume: 3, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial	2008
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert review of anticancer therapy, 2009, Volume: 9, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C	2009
Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology, 2010, Volume: 78 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic;	2010
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Fluoro	2012
[Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf	2002
Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer, 2003, Apr-15, Volume: 97, Issue:8 Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel	2003
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC). Surgical endoscopy, 2003, Volume: 17, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma, Hepatocellula	2003
[The chemotherapy for hepatocellular carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cis	2003
[Recent progress in chemotherapy for hepatocellular carcinoma]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Aug-10, Volume: 93, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C	2004
[Chemotherapy for hepatocellular carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial	2004
Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. Journal of surgical oncology, 2005, Jun-15, Volume: 90, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C	2005
[FAIT (FU arterial infusion and interferon therapy) for hepatocellular carcinoma]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Synergism; Drug Th	2006
[The progress of hepatic arterial infusion chemotherapy for hepatocellular carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr	2006
[Gemcitabine and digestive carcinomas]. Bulletin du cancer, 2007, Volume: 94 Spec No Actualites Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl	2007
[Angiogenesis targeting in gastro-intestinal cancers]. Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C	2007
Safety of capecitabine use in patients with liver dysfunction. Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:9 Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Relate	2007
[Recent developments in systemic chemotherapy for hepatocellular carcinoma]. The Korean journal of hepatology, 2008, Volume: 14, Issue:1 Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabi	2008
[Hepatic tumors]. Acta medica Austriaca, 1983, Volume: 10, Issue:4 Topics: alpha-Fetoproteins; Angiography; Breast Neoplasms; Bronchial Neoplasms; Carcinoembryonic Antigen; Ca	1983
Update on regional treatments for hepatobiliary malignancies. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular;	1995
Cancers of the large bowel and hepatobiliary tract. Cancer chemotherapy and biological response modifiers, 1994, Volume: 15 Topics: Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Pancreatic N	1994
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Annals of surgery, 1995, Volume: 221, Issue:6 Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce	1995
Medical treatment of hepatocellular carcinoma: any progress? Tumori, 1994, Oct-31, Volume: 80, Issue:5 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;	1994
Mitoxantrone, 5-FU + folinic acid, mitomycin C for regional chemotherapy of malignant liver tumors. Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Reg	1996
Intra-hepatic arterial drug delivery. Journal of drug targeting, 1996, Volume: 3, Issue:5 Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Col	1996
Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis? Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:2 Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Ethanol; F	1998
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer, 2001, Jun-15, Volume: 91, Issue:12 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa	2001
Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector. Molecular biotechnology, 2001, Volume: 18, Issue:3 Topics: Adenoviruses, Human; alpha-Fetoproteins; Animals; Antineoplastic Protocols; Antiviral Agents; Carcin	2001
Nonsurgical treatment of hepatocellular carcinoma. Seminars in oncology, 2001, Volume: 28, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoemboli	2001
Systemic therapy for hepatocellular carcinoma. Seminars in oncology, 2001, Volume: 28, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco	2001
[Hepatic arterial infusion chemotherapy using 'low dose FP']. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 6 Topics: Administration, Sublingual; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula	2001
[Adverse reaction of hepatic arterial infusion chemotherapy for hepatocellular carcinoma]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelling; Ci	2001
[Hepatic arterial infusion chemotherapy combined with interferon-alpha for hepatocellular carcinoma]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched	2001
[Chemotherapy of gastrointestinal tumors (review of the literature)]. Onkologie, 1978, Volume: 1, Issue:6 Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl	1978
Therapeutic approaches to hepatoma. Cancer treatment reviews, 1975, Volume: 2, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Drug Synergism; Drug Therapy, Com	1975
The biologic basis of malignant brain tumor therapy. Advances in neurology, 1976, Volume: 15 Topics: Animals; BCG Vaccine; Brain Neoplasms; Carcinoma, Hepatocellular; Culture Techniques; DNA, Neoplasm;	1976
[Selective chemotherapy of hepatocellular carcinomas]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1978, Issue:84 Topics: Animals; Carcinoma, Hepatocellular; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Liver Neopla	1978
[Interdisciplinary therapy concepts in primary and secondary neoplasms of the liver]. Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24 Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Floxuridine; Fluorouracil; Follow-Up Studies;	1989
[Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. Minerva medica, 1989, Volume: 80, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Evaluatio	1989
Medical treatment of hepatocellular carcinoma. Gastroenterology clinics of North America, 1987, Volume: 16, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Co	1987
Systemic cytostatic drug therapy in liver cancer. Annales chirurgiae et gynaecologiae. Supplementum, 1986, Volume: 200 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic;	1986

fluorouracil and Hepatocellular Carcinoma

Research Excerpts

Research

Studies (1,089)

Authors

Clinical Trials (41)

Trial Overview

Trial Outcomes

HBV-DNA < 300 Copies/mL in 48 Weeks

Reviews

Trials

Other Studies